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ABSTRACT
Rituximab (Mabthera®, Rituxan®) is a monoclonal antibody (mAb) against B-cell specific
CD20  antigen.  It  is  used  for  the  treatment  of  B-cell  non-Hodgkin  lymphomas  (NHL)
and chronic lymphatic leukemia. In combination with chemotherapeutics rituximab is the
first-line therapy of several types of NHLs including follicular lymphoma (FL).
Immunochemotherapy has remarkably improved the outcome of NHL patients, but a
vast variation in the lengths of remissions remains and the outcome of individual patients
is difficult to predict. The cause of this variable behavior of tumors is poorly understood.
This thesis has searched for an explanation for this issue by studying the effector
mechanisms of rituximab and by comparing gene expression in lymphoma tissue samples
of patients with long- and short-term survival.
Binding of rituximab to B-lymphoma cell activates cytotoxic cells and the complement
(C) system, and induces apoptosis. In this work we have demonstrated that in cytoxicity
assays C activation is the most efficient effector mechanism of rituximab. Incubation of
rituximab-treated lymphoma cell lines with normal human serum (NHS) but not with
peripheral blood leukocytes (PBL) resulted in significant cytolysis. Rituximab treatment
induced apoptosis in cell-line dependent manner. These assays also showed that C-
mediated cell killing could be markedly improved with simultaneous neutralization of the
C regulatory proteins CD46 (Membrane cofactor protein (MCP)), CD55 (Decay-
accelerating factor (DAF)), and CD59 (protectin) in vitro.
We studied the activation of the C system in vivo in blood and cerebrospinal fluid (CSF)
before, during, and after intravenously administered rituximab. A marked increase in the
concentration of the C activation marker C3a-desArg was measured in blood two hours
after beginning of the first rituximab infusion. Emphasizing the role of C in mediating
the action of rituximab a rapid disappearance of peripheral blood CD20 positive cells
was observed simultaneously with C activation. Intravenously administered rituximab
could not enter the central nervous system (CNS), and neither C activation nor removal
of CD20 positive cells was observed in the CSF. This finding led to the suggestion that it
might be worth of administering rituximab intrathecally to CNS-lymphoma patients.
Because in vitro data suggested that C regulators can affect the efficacy of rituximab, we
conducted clinical studies where the differences in gene expression profiles of lymphoma
tissue and in expression levels of C regulatory proteins were related to the outcome of 24
FL patients treated with immunochemotherapy. Expression of 18000 genes was analyzed
from tumor sample isolated RNA using microarray technique. The patients were divided
into “long-term responders” and “short-term responders”, and the gene expression
patterns between the groups were compared.
8
Lymphoma tissues of different patients were demonstrated to be genetically rather
homogeneous, but the expression of certain genes was associated with different
outcomes. The distinctive genes were often related to cell cycle regulation, signal
transduction or regulation of immune responses. Of the best differentiating genes we
randomly selected SMAD family member 1 (Smad1), macrophage receptor collagenous
structure (Marco; a macrophage scavenger receptor), and Ephrin receptor A1 (EphA1; a
tyrosine kinase involved in transendothelial migration) for further studies. The results
were verified using quantitative polymerase chain reaction (qPCR) and
immunohistochemical stainings. Smad1 and EphA1 were demonstrated to be mainly
expressed in the microenvironment of the tumor cells. The staining intensity of EphA1
correlated to the clinical outcome in the study group of 24 patients and in a validation
group of 40 patients. The results demonstrate that certain lymphoma tissue-associated
factors correlate to the clinical outcome of immunochemotherapy treated FL patients.
They also suggest that evaluation of these factors at the mRNA level using qPCR or at
the protein level can be utilized to identify more specifically the patients for whom
immunochemotherapy most probably is effective.
Low mRNA expressions of C regulators CD59 and especially of CD55 were also
associated with a good prognosis of FL patients in the same data set. When lymphoma
cell  expressions  were  compared,  progression  free  survival  (PFS)  times  of  patients  with
low CD55 or CD59 levels were significantly longer than of those with high expression
levels. The results were verified using flow cytometry analysis in a prospective study of 12
patients. High expression of CD20 relative to CD55 correlated to a longer progression
free survival. The difference between non-responding or early relapsed patients and
patients in remission (after median follow-up of 22 months) became more obvious when
CD20 expression was compared to combined average C regulator expression level. The
results suggest that C regulatory proteins represent a clinically relevant immunotherapy
escape mechanism of lymphoma cells. They also suggest that efficacy of immunotherapy
and immunochemotherapy may be increased by neutralizing the C regulatory proteins.
In conclusion, we have demonstrated that activation of the C system is a clinically
important effector mechanism of rituximab and that the tumor microenvironment and
expression of C regulatory proteins affect markedly the efficacy of
immunochemotherapy. This information can be used to identify more accurately patients
to  whom  immunochemotherapy  is  beneficial.  It  may  also  help  in  the  development  of
rituximab containing therapy, and other monoclonal antibody therapies.
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1 GENERAL INTRODUCTION
The word  cancer  refers  to  a  class  of  diseases  characterized  by  uncontrolled  division  of
cells and ability of the cells to invade and damage normal tissues either locally or at
distant sites of the body. Cancers are rather common: 26000 people in Finland got cancer
in 2004 and 11000 died of it (Finnish cancer registry 2005).
Human body consists of about 1014 cells, many of them dividing and undergoing
programmed  cell  death  (apoptosis)  or  dying  of  other  reasons  all  the  time.  It  has  been
calculated that about one million cells are produced and eradicated every second in our
body. These million divisions are strictly regulated by hormones and growth promoting
or suppressing signals, but all of them are vulnerable to errors, potentially leading to
malignant transformation step by step. In this respect, we can ask: why aren’t cancers far
more common?
Fortunately, multicellular organisms have powerful surveillance mechanisms against
potentially neoplastic cells: DNA replication errors are relatively rare and are actively
repaired. Activation of many oncogenes, along with harmful effects, often activates
apoptotic pathways, and intercellular signaling together with structures of tissue
microenvironment usually restricts disseminated growth.
The  immune  system  is  a  collection  of  specialized  cells  and  substances  that  protect  the
body against potentially harmful invaders such as bacteria, viruses, fungi or parasites, but
it can also recognize and eliminate endogenous objects such as immune complexes or
transformed cells. An essential prerequisite for the development of cancer is that the
tumor  cells  can  evade  immune  elimination.  If  they  succeed  in  this,  cancer  may  be  the
result. Even if immune system by itself is not capable of preventing the growth of
malignancies in these situations, the progress of medical sciences has made it possible for
the body to strike back once more. Various immunotherapeutic approaches can
strengthen the already existing but weak anti-tumor activity or generate an immune
system attack against specifically defined targets.
An intentional exploitation of the immune system for cancer treatment dates back to the
early 20th century, when William B. Coley, a surgeon in New York City, discovered that
malignant tumors disappeared in cancer patients who had contracted streptococcal
infections. He thereafter deliberately infected patients carrying non-treatable malignancies
with killed bacteria, and actually created the first anti-cancer vaccine. Coley’s mixed bacterial
toxin resulted in the regression of tumors in one third of the patients. Unfortunately, his
results were unpredictable, and were slowly forgotten for decades. The science of
immunology was very young on those days, and his observations could not be
mechanistically  explained.  At  the  other  side  of  the  Atlantic  Ocean,  also  during  the  late
19th and early 20th century Paul Ehrlich dreamed of "magic bullet". Using our terminology
General introduction
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he proposed that cells have specific receptors for antigens and that they can shed these
receptors into the blood when they come into contact with antigen. This was the first
time when the nature of antibodies was suggested.
From those days it took almost a century before the first specific immunotherapy against
cancer received acceptance for clinical use. This “magic bullet” was rituximab, a
monoclonal antibody against the B-cell specific CD20 antigen, and it was launched for
the treatment of non-Hodgkin lymphoma. Simultaneously, a whole array of new
unanswered questions emerged for both basic scientists and clinicians to address. What
happens when an anti-tumor antibody recognizes its target? Why don’t all CD20 positive
cells die, even if they have been recognized by rituximab? Why don’t all patients respond
to rituximab? Why the lengths of remissions differ so much between individual patients
even if their primary responses had seemed to be very similar? –The aim of this study
was to investigate these interesting questions.
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2 REVIEW OF LITERATURE
2.1 IMMUNE SYSTEM
The immune system is responsible for protecting the host against potentially harmful
agents. The immune system has traditionally been divided into the innate and adaptive
(specific) parts (Riot, Brostoff & Male 1996). Innate immunity refers to pre-existing
immediate defense mechanisms that the host uses against invading micro organisms and
for clearance of debris. Adaptive immune system responses take weeks to develop, but
the reactions are powerful and aimed accurately against specific targets.
INNATE IMMUNITY
Existing already in ancient organisms, the innate immune system is evolutionary old but
has developed over millions of years to become a clever, complex entity of different
mechanisms. In humans, innate immunity includes mechanical, chemical, humoral and
cellular defense networks. When a microbe is about to invade the body, it first faces the
physical barriers such as skin or mucosal membranes (Male, Roitt 1996). Cilia of the
respiratory tract transfer invading microbes away from the body; mucus traps pathogens
trying to breach the mucosal barriers; lysozyme of tears and saliva destroys bacteria etc.
However, if a microbe has succeeded to invade the body, the cellular and humoral parts
of the innate immune system are immediately alerted and mobilized. The reactions of
innate immunity are fast, because, instead of mounting a response against distinct foreign
antigens, the innate immune system can identify common structures present in many
microorganisms. These structures include lipopolysaccarides of gram-negative bacteria,
bacterial peptidoglycans and viral double-stranded RNA. Cells of the innate immune
system include neutrophils, macrophages, monocytes, dendritic cells, eosinophils,
basophils, mast cells and natural killer (NK) cells. The complement system is an essential
part of humoral innate immunity.
ADAPTIVE IMMUNITY
Adaptive immune system is evolutionary much more novel than the innate immune
system and found only in multicellular organisms. Adaptive immune system is organized
through two classes of specialized cells, T and B lymphocytes, that can recognize a wide
variety of different antigens (Male, Roitt 1996). Reactions of adaptive immune system are
extremely powerful and specific, but they do not usually occur before antigen-presenting
cells (APC) have recognized invading agents and processed them for presentation to T
cells. The reactions take one to two weeks to develop, but simultaneously develops a
long-lasting memory of how to combat efficiently these specific microorganisms.
ANTIBODIES
An antibody is a soluble or B-cell membrane-associated (B-cell receptor) molecule used
by the immune system to identify specifically foreign objects like bacteria and viruses. An
antibody can recognize and bind to antigens on target cell surfaces or in solution. This
Review of literature
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binding can lead e.g. to direct neutralization of a virus, blocking of the function of
antigen or labeling of the target for attack by other parts of the immune system (Turner
1996).
Antibodies are Y-shaped glycoproteins formed by two identical heavy chains and two
identical light chains (Figure 1). Based on different heavy chain constant domains
antibodies are divided into five types with different biological properties and locations:
Immunoglobulin (Ig) A, IgD, IgE, IgG, and IgM.
Fab-regions at the “two arms” of the antibody contain the antigen-binding sites and
define the specificity of the antibody (Figure 1). Fc-region mediates the physiologic
effects of the antibody by binding the complement component C1q and to Fc-receptors
of various cells. Different immunoglobulin classes have different abilities to trigger
complement. Best activators of C system are subclasses IgG1 and IgG3. By binding to
different leukocyte Fc-receptors antibodies can trigger other effector mechanisms such as
phagocytosis, antibody-dependent cellular cytotoxicity and acute inflammatory responses.
The recognition of numerous specific antigens requires a large number of different
antibodies. To enable the generation of required antibody repertoire, specific
mechanisms for their production in B-cells are needed. Availability of multiple V, D and
J genes, their somatic recombinations and somatic hypermutations allow the production
of much larger diversity of antibodies than could be expected based on the availability of
different genes alone (Hay 1996).





The complement system forms an essential part of both the innate and adaptive immune
systems. It is a group of plasma proteins that interact in a cascade-like manner. C system
consists of over 30 soluble and membrane-bound proteins, of which most function as
enzymes, binding proteins, receptors or regulators of activation. The main physiological
functions of complement are (1) protection against infections, (2) generation of
inflammation, (3) bridging between innate and adaptive immunity, and (4) clearance of
immune complexes, damaged cells or other debris (Walport 2001).
When C faces  a  foreign  microbe,  it  becomes  activated  and  the  cascade  can  prodeed  to
generation of membrane attack complexes (MAC) and direct cytolysis. C can also
promote phagocytosis by opsonizing foreign particles with its components C1q, iC3b,
C3b and C4b, and attract and activate leukocytes via releasing chemotactic and
anaphylatoxic agents C5a, C3a.
Target recognition by C occurs often non-specifically and C operates as a part of innate
immunity. On the other hand, antigen- or immunecomplex bound C3b and C4b
molecules can activate B cells, follicular dendritic cells or other antigen-presenting cells
by binding to the CR1 (CD35) and CR2 (CD21) complement receptors, and induce
adaptive immune system reactions. Also, if antibodies have already been generated and
they have recognized their targets, the C system can become activated and direct C
mediated cytolysis can take place.
C ACTIVATION PATHWAYS
The C system can become activated through three distinct routes (Figure 2) (Walport
2001). (I) The classical pathway (CP) usually becomes activated by antibodies. It mediates
specific immune responses and functions as a part of adaptive immunity. (II) The
alternative pathway (AP) forms a major part of the humoral immune system’s natural
defense against infections. It operates continuously at a slow rate in plasma, and becomes
activated abundantly wherever foreign surfaces are present. The alternative C pathway is
an  important  discriminator  between  self  and  non-self  structures  and  can  amplify  C
activation reactions initiated via other pathways. (III) The lectin pathway (LP) also
functions as a part of innate immunity by recognizing mannan and N-acetylglycosamine
residues on microbial surfaces.
Classical pathway
When antibodies bind to their target molecules, they can initiate the CP of complement.
The  CP  is  triggered  when  the  complement  molecule  C1q  binds  to  the  Fc-parts  of
antigen-bound IgM- or IgG-class immunoglobulins. The CP can also be activated
antigen-independently by C-reactive protein (Miyazawa, Inoue 1990) or by surface blebs
of apoptotic cells (Navratil et al. 2001). The binding to antibody causes conformational
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changes in the C1q molecule leading to activation of two C1r proteases and further to
cleavage of two C1s (another serine protease) molecules. The C1-complex now binds to
and  splits  C2  and  C4.  The  cleavage  product  C4b binds  covalently  to  a  cell  surface  and
forms C4bC2 complexes. The activated C1s further cleaves C4bC2 and generates
C4bC2a, which is the classical pathway C3/C5 convertase.
Alternative pathway
In the fluid phase spontaneous hydrolysis of C3 to C3(H2O) occurs continuously at a low
rate (Pangburn, Muller-Eberhard 1983). When C3(H2O) binds to factor B, and factor D
cleaves factor B to Bb, C3(H2O)Bb convertase is generated. This convertase will cleave
C3 to  C3a  and  C3b,  of  which  the  latter  can  bind  to  microbial  surfaces.  The  cascade  is
preceded, when C3b binds to factor B and is cleaved to C3bBb by factor D. The C3bBb
complex is the principal AP C3 convertase, which will produce more C3b and C3a. On
foreign surfaces the lack of C regulatory molecules leads to deposition of C3b molecules
and continuing activation of the alternative complement pathway (Pangburn, Muller-
Eberhard 1984). In this way the target surface will be covered by numerous C3b
molecules. When C3bBb recruits another C3b molecule, a C5 convertase is generated.
Lectin pathway
The lectin pathway is homologous to the classical pathway. This pathway is activated
when mannan-binding lectin (MBL) binds to sugar structures on target surfaces (Petersen
et al. 2000). MBL-associated serine proteases (MASPs) 1 and 2 bind to target-bound
MBL  and  form  a  complex  that  can  cleave  C4  and  C2.  This  generates  the  classical
pathway C3-convertase, C4b2a (Figure 2).
Terminal complement pathway
All C activation pathways lead to the formation of C3/C5 convertases and cleavage of
numerous C3 and C5 molecules. The generated C3b molecules cover the target cell
surfaces favoring phagocytosis and other biological responses, and C5b molecules initiate
the terminal complement pathway.
The terminal complement pathway consists of factors C5, C6, C7, C8 and C9. C5b
molecules  can  bind  in  the  fluid  phase  C6  and  C7  and  on  membranes  C8.  The  C5b-8
complex catalyzes polymerization of multiple C9 molecules to form a pore-like structure
on the target cell membranes (Malinski, Nelsestuen 1989). The generation of membrane
channels, MACs, leads to calcium-influx, leakage of several intracellular substances, loss
of mitochondrial membrane potential, and lysis of the target cell.
Review of literature
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Figure 2. Complement activation pathways
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REGULATION OF COMPLEMENT ACTIVATION
Complement activation must be strictly controlled because C-induced inflammation and
tissue destruction can be harmful to the host. Inappropriate C activation, excessive
inflammation and overconsumption of C components are avoided in normal tissues
mainly by the expression of complement regulatory proteins. The distribution and
importance of different membrane-bound and soluble C regulators vary between tissues
and cell types (Gorter, Meri 1999, Gorter, Meri 1999, Morgan, Meri 1994). Of the
membrane bound regulators CD46 (Nicholson-Weller et al. 1982, Nicholson-Weller et al.
1985), CD55 (Seya, Turner & Atkinson 1986, Sugita, Nakano & Tomita 1988), CD59
(Davies et al. 1989, Holguin et al. 1989, Meri et al. 1990), and of the soluble regulators
factor H (Fontaine, Daveau & Gilbert 1983) and C4 binding protein (C4bp) are best
characterized and considered as most important. The major C regulators are listed in
Table 1.  The different regulators affect  the progress of C activation at  different phases,
and therefore their actions are often synergistic. In addition to C regulators also other C
regulation mechanisms exist. E.g. MAC complexes can be eliminated from plasma
membranes by endocytosis and by vesiculation (Campbell, Morgan 1985, Scolding et al.
1989, Sims, Wiedmer 1986).
Table 1. A list of most important soluble and membrane-bound C regulators.
Soluble regulators Main function
C1-inhibitor Binds and inactivates C1r and C1s
C4-binding protein Inhibits formation and inactivates classical
pathway C3 convertase
Factor H Inhibits formation and inactivates
alternative pathway C3 convertase
Factor I Cleaves and inactivates C3b and C4b
Vitronectin Inhibits binding of terminal complement
complex to cell membranes
Clusterin Inhibits binding of terminal complement
complex to cell membranes
Membrane-bound regulators Main function
CD35 (Complement receptor 1)
Dissociates alternative and classical
pathway C3/C5 convertases,
cofactor for factor I
CD46 (MCP) Cofactor for factor I
CD55 (DAF) Dissociates alternative and classical
pathway C3/C5 convertases





CD46 or the membrane cofactor protein is a 51-68 kDa glycoprotein consisting of four
extracellular short consensus repeat (SCR) domains, a membrane-proximal region, a
transmembrane  domain,  and  an  intracellular  cytoplasmic  tail.  The  gene  for  MCP  is
located in chromosome 1. CD46 gene forms a “regulators of complement activation”
(RCA) gene cluster (1q32) together with genes of other C regulators with SCR domains
(Rodriguez de Cordoba et al. 1985). Probably generated by alternative splicing and
glycosylation,  CD46 can  be  present  on  the  same cells  in  different  isoforms  (Post  et  al.
1991). The biological meaning of this is not known.
CD46 is expressed by almost all nucleated cells, including leukocytes, but is not present
in  erythrocytes  (Seya  et  al.  1988).  It  acts  as  a  cofactor  for  factor  I  and  thus  promotes
cleavage  of  C3b to  iC3b,  and  of  C4b to  C4c  and  C4d.  Thereby  CD46 functions  as  an
inhibitor of CP and especially of the AP C3/C5 convertases (Kojima et al. 1993).
CD55
CD55 or decay-accelerating factor is a 190-220 kDa membrane glycoprotein. It also
belongs to the RCA-group. CD55 has four SCR domains and a glycosyl-phosphatidyl-
inositol- (GPI-) anchor that links it to membrane phospholipids (Caras et al. 1987, Medof
et al. 1986). CD55 is distributed widely in different tissues, but usually less abundantly
than CD46. It is also expressed in erythrocytes, but is absent from some T cells and NK-
cells (Nicholson-Weller, Russian & Austen 1986, Tomita, Okada & Okada 1991). In
addition to GPI-anchored form also a soluble form of CD55 lacking the GPI-anchorlipid
is found in serum and other body fluids (Medof et al. 1987).
The main function of CD55 is to inhibit C activation at the C3 level by accelerating the
decay  of  both  CP  and  AP  C3/C5  convertases  (C4b2a  and  C3bBb).  Besides  the  C
inhibiting function, CD55 has also been shown to promote tumorigenesis (Loberg et al.
2006) and to inhibit function and migration of NK and T cells (Kusama et al. 2003,
Mikesch et al. 2006, Spendlove et al. 2006).
CD59
CD59 or protectin is a 18-23 kDa GPI-anchored membrane glycoprotein. Not consisting
of SCRs but of another distinct domain, it differs structurally from CD46 and CD55. The
CD59 gene  is  located  in  chromosome  11p13.  CD59  was  first  isolated  from  human
erythrocytes, but has later been found on all circulating cells and widely also on
endothelial cells, and epithelial cells (Davies et al. 1989, Meri, Waldmann & Lachmann
1991). In addition to the GPI-lipid anchored form, there is a soluble form of CD59,
which has been detected in various body fluids including urine, tears, and saliva. CD59
represents the last line of defense against C activation. It can bind to C8 or C9 and




The immune system is much better in recognizing foreign organisms than body’s own
transformed or mutated cells. Nevertheless, studies of the immune system have revealed
that the human body defends itself against cancer principally in much the same way as it
does when eliminating invading microbes.
In the late 1950s Frank MacFarlane Burnet (Burnet 1970) and Lewis Thomas (Thomas
1982) separately launched the theory of immunosurveillance. They hypothesized that the
immune system is continually surveying for abnormal cells. Precancerous and cancerous
cells are in most cases recognized as non-self structures, and destroyed. Along their
theory, it is a rare phenomenon that sufficient amounts of tumor cells manage to escape
the  immune  system,  but  if  they  do,  cancer  is  the  result.  The  observations  that
transplantation  of  tumor  tissue  between  syngeneic  animals  lead  to  rejection,  but  that
transplantation of normal tissue does not, revealed the existence of tumor-associated
antigens (TAA). Later the theory was criticized from several directions. In 1970s,
differences in tumorigenesis between immunocompetent and partly immunodeficient
mice were not observed (Stutman 1974, Stutman 1979) and the immunosurveillance
theory was almost abandoned. Many oncologists and scientists believed that instead of
immune system other innate fail safe-mechanisms prevent tumors from arising that
often. They thought that the immune system usually cannot recognize precancerous cells
as foreign and therefore cannot have such a central role in tumor elimination.
There were, however, certain epidemiological and other observations, that suggested that
immune system might still have some impact. (I) The incidence of some malignancies
(e.g. Kaposi’s sarcoma and immunoproliferative diseases) is increased in
immunodeficient patients (Boshoff, Weiss 2001). (II) Cancer more often develops in
young children or senior citizens – groups of people also having weaker immune
defenses (Finnish cancer registry 2005).  (III) Certain tumors sometimes regress
spontaneously  (e.g.  melanoma,  renal  cell  carcinoma)  (Papac  1996)  –  it  has  been
speculated that only immune reactions can explain these “miraculous” healings. (IV)
Anti-tumor antibodies and immune T-lymphocytes have been detected in cancer patients
(Bremers, Parmiani 2000). These observations suggest that immune responses develop
against some types of tumors, particularly against those, where viruses play a role in
tumor development.
New studies in mice in the 1990s and early 21st century have brought back the ideas of
immunosurveillance. They have demonstrated that mice really lacking an intact immune
system generate more spontaneous and chemically-induced tumors than
immunocompetent mice. In addition, tumors from immunodeficient mice are more
immunogenic than those from wild type mice. Broadly based on these observations
Dunn and his colleagues (Dunn, Koebel & Schreiber 2006, Dunn, Old & Schreiber
2004a, Dunn, Old & Schreiber 2004b) have proposed a theory of cancer immunoediting, in
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which the interaction between a developing tumor and host immune system is comprised
of three phases. The elimination phase resembles the actions described within the
immunosurveillance theory. The innate and adaptive arms of the immune system can
recognize and kill most of the transformed cells, and reject the tumor. If the elimination
is incomplete and some malignant cells survive, immunoediting proceeds to an equilibrium
phase. In the equilibrium phase residual cancer cells persist, but an immune pressure
prevents  them from expanding  and  generating  a  clinical  disease.  This  stage  can  last  for
years, and the disease can stay in clinical remission. But if the balance is once lost and the
tumor cells start growing progressively, the process proceeds to an escape phase. The
escape can occur, if new (e.g. oncogenic) mutations take place, if tumors develop new
immune escape mechanisms, or if the immune system is exhausted. In this situation the
immune system cannot control the tumor growth, and a relapse or wide-spread disease
results.
Another question is how are malignant cells recognized in the first place? Most scientists
believe that tumors express “non-self” antigens, i.e. newly mutated antigens or antigens
expressed only at low levels by normal cells. If such antigens are detected by the immune
system, an immune response also needs a secondary signal to be generated efficiently.
The innate immune system can provide the secondary stimulation through up-regulation
of co-stimulatory molecules in APCs (Lafferty, Cunningham 1975). According to the
self/non-self discrimination theory, APCs can trigger the adaptive immune system after
recognizing conserved molecular patterns usually associated with evolutionary distant
structures such as microbial surfaces. And it is the lack of this signal that in the case of
cancer prevents an immune response to take place.
According to another theory, the so called danger model, the immune system is stimulated
by endogenous signals that originate from stressed or injured cells (Fuchs, Matzinger
1996,  Matzinger  1998).  For  instance,  an  abnormal  damage  of  cells  is  a  signal  for  local
APCs to takeup local antigens and to upregulate the costimulatory molecules needed for
activation of T cells. During metastasis and invasion of malignant cells, natural tissue
barriers are disrupted, and proinflammatory signals are released. This can induce an
immune response against these cells without the discrimination between self and non-
self.
COMPLEMENT AND CANCER
Limited information is available about the tumor immunosurveillance function of C. In
principle the C system has the ability to destroy tumor cells, but compared to cell-
mediated adaptive immunity it has much less discriminating power between self and
foreign.  No  clear  evidence  that  C  would  have  a  clinically  important  role  in  protection
against cancer, nor associations between C deficiencies and an increased cancer
incidence, has been published. However, various C abnormalities such as elevated plasma
C3  levels  in  brain  tumor  patients  (Matsutani  et  al.  1984)  and  lung  cancer  patients  and
reduced complement titers in breast, gastric and colon–rectum carcinoma patients
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(Mangano et al. 1984) have been described. Also C deposits within the tumor tissue,
especially in necrotic areas, have been found in e.g. breast (Niculescu et al. 1992),
papillary thyroid (Lucas et al. 1996), and renal (our unpublished data) carcinomas.
Furthermore, Varga and her colleagues demonstrated that low pre-treatment classical
pathway C levels correlated unfavorably to long-term prognosis of chronic lymphatic
leukemia  (CLL)  patients  (Varga  et  al.  1995).  None  of  these  observations,  however,
provides evidence that tumor cells by themselves could activate the C system in vivo, or
that the C system could affect the growth or development of tumors. It is possible that
the C system becomes activated in the tumor tissue indirectly by immune complexes,
necrotic cells or substances generated by tumors. In the studies by Varga infections were
also more common in patients with low C activity. Therefore it was hypothesized that it
may also be the increased susceptibility to infections that explains the unfavorable
prognosis of CLL patients with low classical pathway C levels.
C RESISTANCE MECHANISMS OF TUMORS
Even if the C system would not be the major factor responsible for tumor growth
restriction, it is fundamental for malignant cells to have mechanisms to resist C attack in
vivo. Several different C escape mechanisms of tumors have been found or proposed.
Most importantly, malignant cells are protected against C by membrane-associated and
soluble C regulatory proteins. Other less thoroughly characterized C escape mechanisms
include membrane expression of ecto-proteinases, which can control C3 deposition (Jean
et al. 1995, Jean et al. 1996, Ollert et al. 1990), or kinases that can phosphorylate C9 and
affect MAC formation (Paas, Bohana-Kashtan & Fishelson 1999). Tumor cells can also
secret proteochondroitin sulfate, which inhibits formation of the C1 complex (Kirschfink
et al. 1997). It has also been demonstrated that sublytic amounts of MAC cause various
biological effects including an increased resistance to C lysis. This resistance has been
associated with an increase in intracellular Ca2+ levels, and activation of cytoplasmic
protein kinase C (PKC), MAP kinase (MAPK) and protein synthesis (Fishelson, Kraus
1998). In addition, shedding of C3b-bound surface molecules or formation of MAC-
containing vesicles may provide protection against C attack (Whitlow, Klein 1997).
Expression of membrane bound and soluble C regulators in tumors
All hematological malignancies and the majority of solid tumors express at least some of
membrane bound C regulators, that include CD46 (MCP), CD55 (DAF), and CD59
(protectin). The expression levels of C regulators in malignant tumors are usually equal
to, or greater, than seen in the surrounding normal tissue (Bjørge et al. 1997, Hakulinen,
Meri 1994, Hofman et al. 1994, Jarvis et al. 1997). Membrane expression of C regulators
has been demonstrated e.g. in glioma (Junnikkala et al. 2000, Mäenpää et al. 1996),
carcinomas of thyroid gland (Yamakawa et al. 1994), breast (Hakulinen, Meri 1994,
Hofman et al. 1994), ovary (Bjørge et al. 1997), lung (Niehans et al. 1996) cervix
(Simpson et al. 1997), colon (Koretz et al. 1992, Koretz et al. 1993), and kidney (Niehans
et al. 1996) and in leukemias and lymphomas (Fukuda et al. 1991, Hara et al. 1992, Seya
et al. 1994). Interestingly, deficiencies in C regulators have also been reported in a subset
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of  breast  cancers  (Hofman  et  al.  1994),  and  some  NHLs  were  reported  to  lack  CD55
expression (Fukuda et al. 1991, Hara et al. 1992, Seya et al. 1994).
Soluble forms of CD46, CD55 and CD59 have been found in various body fluids.
Release of these soluble forms can either augment the local complement inhibitory
potential of tumors or reduce the C regulatory function of tumor cells. Hakulinen et al.
demonstrated that shedding of CD46 from cell membranes is regulated by a disintegrin
and metalloproteinase (ADAM) 10 (Hakulinen, Keski-Oja 2006). ADAM10-mediated
release  of  CD46  was  stimulated  e.g.  during  apoptosis,  and  led  to  reduction  of  C
regulation capacity of these cells.
Factor H (fH) and other mainly soluble C regulators are also involved in tumor cell
resistance against C (Junnikkala et al. 2002). Certain tumor cells have been shown to bind
fH molecules from circulation and in that way increase their C resistance (Junnikkala et
al. 2002).
External modulation of C regulator expression
Expression levels of C regulators may be influenced by host-derived and
microenvironmental factors such as hormones, growth factors, and cytokines. For
example interferon-  (IFN ) has been shown to increase CD59 and CD55 expression in
gastrointestinal tumor cells (Schmitt et al. 1999) and interleukin-1  (IL-1 ) has been
found to upregulate CD46 expression in colon carcinoma (Bjørge et al. 1995). Tumor
necrosis  factor-  (TNF ),  IL-1 ,  and  IL-6  have  been  demonstrated  to  increase  the
expression of CD55 and CD59, but to decrease the expression of CD46 in hepatoma
cells (Spiller et al. 2000). Also, hypoxemia has been reported to reduce the expression of
CD59 (Väkevä, Meri 1998). On the other hand in colorectal cancer it has been reported
that hypoxia induces COX-2 expression and increases prostaglandin E2 levels, which
further upregulates the expression of the complement inhibitor CD55 (Holla et al. 2005,
Liu et al. 1999). Undoubtedly information about the modulation capacity of cytokines
and the effect  of oxygen supply are limited,  and based on these individual  findings it  is
difficult to evaluate the clinical importance of the phenomenon.
2.4 IMMUNOTHERAPY
Cancer immunotherapy aims at exploiting the therapeutic potential of tumor-specific
antibodies and humoral or cellular immune effector mechanisms. In active
immunotherapy an endogenous, long-lasting immune response is induced, whereas in
passive immunotherapy ex vivo produced immune system components such as
antibodies are used. Besides this division different immunotherapeutic methods can also
be divided into specific and non-specific immunotherapies. In non-specific
immunotherapies existing or naturally-induced immune reactions are strengthened by
humoral or cellular factors. In specific immunotherapies the target cells are attacked with





Cytokines can affect the growth of tumor cells either directly or via activating cells of
innate or adaptive immune system. As examples of direct effects TNF- , IFN-  and ,
and IL-4 and 6 can induce tumor cells to commit suicide or to stop further growth. IFN-
 has been studied for the treatment of metastatic melanoma, renal cell carcinoma and
follicular lymphoma (Rohatiner et al. 2005).
Clinically more important applications have involved indirect effects of cytokines. Most
importantly, IL-2 has been observed to strengthen anti-tumor immune responses via
promoting the growth and activation of T-cells and NK cells. IL-2 has been used in the
treatment of metastatic melanoma and renal cell carcinoma, often together with
chemotherapeutics. IFN- 2b has been approved for the treatment of Kaposi’s sarcoma
and certain subtypes of leukemia (Hurley, Chapman 2005, Yang et al. 2003). Often side
effects have been found to be a problem in cytokine treatments, but combinations of
different cytokines have had synergistic effects with fewer side effects.
Lymphokine-activated killer (LAK) cell and tumor-infiltrating lymphocyte (TIL)
therapies
Human peripheral blood mononuclear cells (PBMCs) can be isolated, treated ex vivo with
IL-2 to generate lymphokine-activated killer (LAK) cells, and then re-injected to the
patients. Sometimes even complete tumor regressions have been observed (Rosenberg et
al. 1993). After initially promising results clinical studies have later failed to show enough
efficacies (Weber et al. 1992).
To improve the results of immunotherapies new strategies to select more accurately the
anti-tumor-lymphocytes have been proposed. In tumor-infiltrating lymphocyte (TIL)
therapy lymphocytes are collected from inside of surgically removed tumor tissue, grown
in laboratory conditions, treated with IL-2, and injected back to the patient. TILs have
being tested for example in clinical trials of melanoma and renal cell carcinoma (Dudley
et al. 2002, Dudley et al. 2005, Rosenberg, Spiess & Lafreniere 1986), but the responses
have been only moderate. Probably because the production of TILs is technically
difficult randomized trials are still missing (June 2007).
SPECIFIC IMMUNOTHERAPIES
The T and B cell based components of the immune system can induce specific immune
responses against tumors.
Adoptive transfer of T cells
In the so called adoptive transfer, tumor antigen-specific T cells are selected and isolated
from cancer patients. Analogously to the above mentioned LAK and TIL therapies the
cells are expanded in test-tubes and re-infused back to the patient to kill the remaining
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tumor cells. Clinical studies have shown promising results in metastatic melanoma
(Morgan et al. 2006).
Vaccination
Cancer vaccines are cells, parts of cells, antigens (individual or mixed) or DNAs, which
are injected into the body to trigger hosts’ own immune system to respond against
tumors. The mounted reactions are not generalized but specific, affecting only the cancer
cells. Successful cancer vaccines can induce the immune system to make antibodies or
killer T cells against specific anti-tumor antigens. To strengthen the immune responses,
vaccines may be combined with adjuvants.
Tumor cell vaccines. Tumor cell vaccines are prepared after surgery of the primary
tumors. Malignant cells from tumors are separated, killed and re-injected into the patient
to stimulate a specific immune response against any similar cancer cell remaining in the
body. These vaccines are autologous, but tumor cell vaccines can also be allogeneic. In
this case the cancer cells, usually removed from several donors, are used along with
adjuvants to stimulate the immune system.
Dendritic cell vaccines. T cells can only recognize antigens that have been processed
and  presented  to  them  by  APCs.  Therefore,  dendritic  cells  (DCs)  and  other  APCs  are
potentially suitable tools as vaccines against cancer. DCs are first isolated from the
patient, and then exposed to tumor antigens (also derived from patients) ex vivo. The
transfer of these antigen-loaded DCs back to the patient can induce significant tumor-
specific immune responses. The technique has been demonstrated to be effective in
some smaller  clinical  trials  (Banchereau  et  al.  2001,  Yu  et  al.  2001),  but  failed  to  show
effect in an important phase III melanoma trial (Gilboa 2007, Schadendorf et al. 2006).
Protein- and peptide vaccines. In antigen vaccines the immune system is stimulated by
specifically selected antigens instead of whole tumor cells. In peptide vaccines the tumor
antigens are processed to resemble epitopes presented by major histocompatibility
complex (MHC)-molecules and injected to the patients together with appropriate co-
stimulatory molecules. The main advantage of peptide-based vaccines is that they are not
patient-specific and they can raise immune responses against particular antigens without a
risk of infusing dangerous substances into the patient.
Anti-idiotype vaccines. B-cell malignancies arise from a single B-lymphocyte clone and
therefore  all  lymphoma  cells  carry  the  same  unique  immunoglobulin  on  their  surfaces.
These  immunoglobulins  can  be  used  as  targets  for  vaccination.  The  challenge  is  that  a
customized vaccine should be prepared for each patient. New technologies, in which the
idiotype genes are amplified and cloned by PCR, and then transfected to cell cultures,
have provided better possibilities for production of idiotype vaccines. In recently
published clinical study idiotypic vaccination induced specific immune responses with
clinical benefit for follicular lymphoma patients (Inoges et al. 2006, de Cerio et al. 2007).
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DNA vaccines. DNA vaccines are bacterial plasmids including DNA that codes for
desired  antigens.  Injected  DNA  makes  the  body  to  produce  itself  the  proteins  against
which an immune response will develop. DNA vaccines can be designed to induce
different effector pathways against tumor targets. They may e.g. induce production of
antibodies against cell-surface antigens or activate cytotoxic T lymphocytes to respond
against intracellular antigens expressed only as MHC class I-associated peptides. To
amplify anti-tumor immune responses genes encoding foreign proteins may be fused to
tumor-derived sequences. DNA fusion gene vaccines have been designed against B-cell
malignancies by fusing idiotype-related single-chain Fv sequence to tetanus toxin-derived
fragment C (King et al. 1998, Spellerberg et al. 1997). Pivotal clinical trial in follicular
lymphoma showed promising results (Stevenson et al. 2004).
Monoclonal antibodies
Monoclonal antibody therapy is passive immunotherapy, in which antibodies against
tumor-specific antigens are produced in the laboratory and infused into the patients. The
target antigens are molecules selectively or abundantly expressed in the tumor cells or in
the type of cells from which the tumor is derived. To achieve a clinical effect, large
amounts of antibodies are needed, but the hybridoma and cell culture techniques provide
possibilities for large scale antibody production.
When a suitable candidate antigen for immunotherapy has been found, monoclonal
antibodies can be developed by immunizing mice with it. Mouse B-cells are harvested
after immunization and fused with a mouse myeloma cells to produce hybridomas. The
unique cell that produces antibodies against the desired target is selected. When this
single hybridoma cell is multiplied, numerous identical hybridoma cells producing
identical antibodies, monoclonal antibodies are obtained (Kohler, Milstein 1975). Genetic
engineering, like the development of strong promoters, has increased the productivity of
these cultures, and nowadays sufficient amounts of antibodies for commercial use can be
produced.
Monoclonal antibodies are consumed upon binding to target antigens and have a limited
life-span. Therefore repeated infusions to the patients are needed. However, repeated
application of foreign antibodies to humans poses a threat of inducing antibody
responses against the injected antibodies themselves (Frodin, Lefvert & Mellstedt 1992).
The risk has been diminished by developing chimeric and humanized antibodies.
Chimeric antibodies are constructed by combining the mouse antibody-derived Fab part
with human antibody Fc-region, whereas in humanized antibodies only the six antigen-
binding polypeptide loops are of non-human origin.
The biologic effects of monoclonal antibodies are multiple. They may crosslink the target
antigens, neutralize soluble signaling proteins, block receptor binding sites or induce
apoptotic pathways. E.g. trastuzumab (Herceptin) can inhibit the growth of breast cancer
cells by binding to human epidermal growth factor receptor 2 (HER2) (Hudis 2007).
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HER2 signaling promotes cell proliferation and trastuzumab binding has been suggested
to decrease HER2 signaling by preventing HER2-receptor dimerization, by inhibiting
shedding of extracellular domain of HER2 receptor or by promoting endocytotic
destruction of the receptor. Some models have also suggested that trastuzumab can
recruit immune effector cells.
Therapeutically one of the most important functions of monoclonal antibodies is indeed
the ability to activate leukocytes or the complement system. Immunoglobulins of
different classes have different abilities to activate complement and Fc-receptor carrying
cytotoxic cells. The most potent C activating antibodies are IgG subclasses IgG1 and
IgG3 (Wallace, Howell & Fanger 1994). Therefore, antibodies of these types are most
commonly used as immunotherapeutic agents. The mechanisms whereby antibodies can
mediate target cell damage are multiple (Figure 3). In complement dependent cytotoxicity
(CDC) antibodies activate the C system, and if C activation is not restricted, it proceeds
to formation of MAC and lysis of the target cell. In antibody-dependent cellular
cytotoxicity (ADCC) monocytes, macrophages, NK-cells and other cytotoxic cells can
recognize Fc-parts of tumor-bound antibodies with their Fc-receptors become activated
and kill the targets. The complement system and cellular mechanisms can also act
synergistically. In complement-dependent cellular cytotoxicity (CDCC) cell-mediated
cytotoxicity or phagocytosis is facilitated, when phagocytes or cytotoxic cells recognize
deposited C components C1q, C3b, inactivated C3b, and/or C4b. Moreover, the immune
reactions are further enhanced, because C factors C3a and C5a are chemotactic and cell-
activating anaphylatoxins.
Figure 3. The major effector mechanisms of antibodies.
CDC = Complement dependent cytotoxicity, ADCC = Antibody-dependent cellular cytotoxicity,
CDCC = Complement dependent cellular cytotoxicity, MAC = Membrane attack complex, FcR
= Fc-receptor, CR1 = Complement receptor 1 and C1qR = C1q-receptor)
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The technique of monoclonal antibodies was developed in the 1960s, but it was not until
1997 in the USA and in 1998 in Europe, when the first anti-tumor monoclonal antibody,
namely rituximab against B-cell type non-Hodgkin lymphomas, was approved for clinical
treatment. The mechanisms of action as well as the therapeutic use of rituximab are
described in detail in forthcoming chapters. After rituximab several antibodies have
received approval for clinical use, and tens are in clinical trials. The antibodies accepted
for cancer therapy are listed in Table 2.
Table 2. Clinically used monoclonal antibodies in treatment of cancer.
(EGFR=Epidermal growth factor receptor, VEGF=Vascular endothelial growth factor,
AML=Acute myelogenous leukemia).
Antibody Trade name Approved Specificity Indication
Rituximab Mabthera/Rituxan 1997 CD20 B-NHL
Trastuzumab Herceptin 1998 HER2/neu Breast cancer
Gemtutzumab Mylotarg 2000 CD33-
calicheamicin
AML
Alemtuzumab MabCampath 2001 CD52 CLL
Ibritumomab
tiuxetan
Zevalin 2002 CD20-90Yttrium B-NHL
Tositumomab Bexxar 2003 CD20-131Iodine B-NHL
Cetuximab Erbitux 2004 EGFR Colon carcinoma
Bevacizumab Avastin 2004 VEGF Colon carcinoma
If target antigen distribution in normal cells is limited, monoclonal antibody triggered
reactions are often specific and cause only rarely systemic toxicity. If side effects are
encountered, they are usually relatively mild, and are often related to the first injection
only. The most typical side effects of commercially available mAbs include fever, chills,
vomiting or rashes.
In addition to plain antibodies, also conjugated antibodies are produced for therapeutic
use against cancer. In conjugated antibodies, the tumor specific antibody acts as a carrier
of chemotherapeutic, toxic or radioactive agents (Table 2).
2.5 NON-HODGKIN LYMPHOMAS
Non-Hodgkin lymphomas are a heterogeneous group of malignancies that originate from
the lymphoid system. The incidence of NHLs has increased during the last decades.
NHL was the sixth most frequent type of cancer in men and the seventh in women in
Finland in 2005 (Finnish cancer registry, 2005). There were about 10 new cases per
100,000 individuals each year.
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Non-Hodgkin lymphomas are clonal malignant expansions of B or T cells of various
stages of maturation. World Health Organization (WHO) classification divides NHLs
into 30 different entities based on cellular morphology and cell lineage (Table 3) (Harris
2001).  T/null-cell  NHLs  are  rare  and  B-cell  NHLs  comprise  nearly  90%  of  all  NHLs
(The Non-Hodgkin's Lymphoma Classification Project 1997). Based on different clinical
behavior NHLs can be divided into indolent and aggressive types (Hiddemann et al.
1996). Indolent lymphomas have a relatively good prognosis with a median survival of 10
years, but advanced stages are considered incurable (at the time of diagnosis most
patients have an advanced stage disease). The most frequent type of indolent lymphomas
is follicular lymphoma. Aggressive NHLs grow rapidly and would often be fatal within
two years if not appropriately treated (Chan 2001). The 5-year survival of patients with
aggressive NHL is shorter than of those with indolent disease, but about half of the
patients with aggressive NHL are cured. The most frequent subtype of aggressive
lymphomas is diffuse large B-cell lymphoma (DLBCL).
Table 3. Basic characteristics of the most common types of non-Hodgkin lymphomas.
The data is adapted from The Non-Hodgkin’s Lymphoma Classification Project (The Non-
Hodgkin's Lymphoma Classification Project. 1997) and bases on a large multicenter study
conducted between 1988 and 1995 when rituximab and other novel treatment regimens were
not available. (MALT=Mucoid associated lymphoid tissue, CLL= Chronic lymphatic











Diffuse large B-cell 30.6 64 45/55 46 41




Marginal zone B-cell, (MALT) 7.6 61 55/45 74 60
Small B-lymphocytic (CLL) 6.7 65 47/53 51 25
Mantle 6.0 63 26/74 27 11
Peripheral T-cell 7.0 56 44/56 26 24
All other types 20.0
PATHOGENESIS
The activation of oncogenes is essential for the development of lymphoid malignancies.
Proto-oncogenes are normal genes usually related to proliferation, cell cycle control, or
apoptosis. They have a potential to become oncogenes after amplification, point
mutations, or chromosomal translocation. Oncogenes often modify a signaling pathway
leading to an altered relay of extracellular messages to nucleus. Over- or underexpression,
or inappropriate control of pathway components leads to dysregulation of cell growth.
Distinct oncogenes have been associated with certain types of NHLs. For example, the
t(14;18)(q32;q21) translocation leading to increased expressions of the anti-apoptotic
protein Bcl-2 has been associated with FL, t(11;14)(q13;q32) translocation leading to
cyclin D1 overexpression has been associated with mantle cell lymphoma (MCL), and
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t(8;14) translocation leading to constitutive expression of myc gene has been associated
with Burkitt lymphoma. The absence or presence of these translocations has been
utilized as markers in diagnostics, and an intentional modulation of these oncogenes or
pathways may offer therapeutical possibilities.
In some cases, NHLs are associated with chronic inflammatory diseases such as Sjögren’s
syndrome, celiac disease or rheumatoid arthritis, and sometimes with chronic infections
caused by pathogens such as Epstein-Barr virus (Burkitt, AIDS-related, primary central
nervous system and some other lymphomas) and Helicobacter pylori (gastric MALT
lymphoma). Also immune suppression e.g. in the case of HIV infection and in high-dose
posttransplant immune suppression therapy, has been shown to be associated with
increased incidence of NHL.
2.6 FOLLICULAR LYMPHOMA
FL accounts for about 22 to 35% of all malignant lymphomas of adults in the Western
world being the second most common type of NHL. Most patients are over 50 years of
age at the time of diagnosis. No difference in the incidence between genders exists, but
FL is twice as common in Caucasians as in Afro-Americans.
FL is derived from germinal center B lymphocytes. A morphological examination of
excisional biopsy specimens usually provides the diagnosis. The diagnosis is based on
morphology, immunophenotype, and genetic and clinical features of the disease. In the
WHO classification (Harris 2001) FL is subdivided into 3 grades depending on the
relative  number  of  centroblasts  in  the  lymphoma  samples  (Table  3).  Grade  3  is  often
further subdivided into 3a and 3b, in which solid sheets of centroblasts can be observed.
Excluding the more aggressive Grade 3b disease, FL is considered an indolent disease. It
typically presents with slow progression and painless peripheral lymphadenopathy. Many
patients are relatively asymptomatic at the time of diagnosis, even if the disease has
progressed to an advanced stage. Bone marrow involvement in FL is frequent, and
splenomegaly is seen in about 30 to 40 % of patients. Otherwise extranodal involvement
is  rare  at  the  early  stage  but  relatively  common  during  the  later  course  of  disease.
Systemic “B-symptoms” such as fever, night sweats, and weight loss are generally
associated with a heavy tumor burden.
FL usually responds well to primary treatment, but relapses are common. Over the
clinical course the disease typically develops resistance to therapy or transforms into the
more aggressive DLBCL form. Excluding patients with localized disease, FL is
considered to be incurable. The median survival is 8 to 10 years.
If diagnosis needs confirmation, cytogenetic studies can be performed. The t(14;18)
(q32;q21)  translocation has been identified in 85 to 90% of FLs  (Horsman et al. 1995,
Rowley 1988). It results in the overexpression of Bcl-2 and protection from apoptosis.
The translocation transfers the bcl-2 gene to the immunoglobulin heavy chain gene locus,
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where it is placed under the immunoglobulin gene enhancer. The new placement of the
gene leads to constitutively high expression of Bcl-2. The Bcl-2 overexpression by itself it
is not sufficient to initiate tumorigenesis. An accumulation of other genomic alterations is
needed for a malignant transformation.
EVALUATION OF PROGNOSIS
Staging
One of the most important factors with respect to selection of appropriate treatment and
evaluation of prognosis is the stage of the disease. The staging of FL is performed
according to Ann Arbor classification. The system is based on the distribution and
number of involved sites and presence or absence of extranodal disease. Stages I and II
represent an early stage disease on the same side of the diaphragm and stages III and IV
an advanced stage disease. The staging is often accompanied by an appendix A or B
indicating the absence or presence of B-symptoms including fever (over 38 °C without
relation to any infection), night sweats, and loss of body weight (>10% / 6 months) (The
Non-Hodgkin's Lymphoma Classification Project. 1997).
Prognostic indices
The outcome of patients has mainly been predicted using clinical prognostic indices. The
International  Prognostic  Index  (IPI)  was  initially  designed  for  aggressive  NHLs,  but  it
has also been applied for FL. To calculate the IPI value age, serum LDH level,
performance status, Ann Arbor stage, and the number of extranodal sites of disease are
evaluated. The fact that the IPI score can classify only 10 to 15% of FL patients into a
group with poor prognosis (IPI score > 3) diminishes the prediction power.
In order to recognize better those FL patients who need more intensive treatment, a new
prognostic factor model Follicular Lymphoma International Prognostic Index (FLIPI)
was proposed (Solal-Celigny et al. 2004). The five factors of FLIPI-index are: age (>60
years), hemoglobin level (<120 g/l), lactate dehydrogenase (LDH) level (above normal),
stage of disease (I-II, vs. III-IV), and the number of nodal sites (  4 vs. <4). The index
divides the patients into three risk groups: low risk patients (0-1 adverse factor; 36% of
patients; 5-year OS 90.6%), intermediate risk patients (2 factors; 37% of patients; hazard
ratio (HR) of 2.3;  5-year OS 77.6),  and poor risk patients (> 3 adverse factors;  27% of
patients; HR of 4.3; 5-year OS 52.5).
TREATMENT OF FOLLICULAR LYMPHOMA
Early-stage disease
FL patients with an early-stage disease (I or II) are usually treated with radiation therapy.
A  typical  dose  is  about  26  Gy,  but  also  a  low  dose  radiation  (4  Gy  or  2x  2  Gy)  can
produce excellent palliation (Haas et al. 2003). The toxicity of this treatment is reasonably
limited and about half of the patients remain free of relapses for more that 10 years
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(Wilder et al. 2001). Relapses after 10 years are rare, and most of the patients surviving
the first 10 years die of other than lymphoma or treatment-related causes.
Advanced-stage disease
Because some patients with an advanced-stage disease (stage III and IV) are also
asymptomatic,  the  first-line  therapy  for  advanced  FL  varies  from  observation  to
combination chemotherapy or immunochemotherapy. For asymptomatic patients with a
slowly-growing disease a watch and wait period following diagnosis may be the best
option. This is a possible choice, because chemotherapy is not curable, and because the
use of it affects the quality of life, contains a potential risk for myelosuppression, chronic
fatigue, and secondary leukemia. In some studies no significant differences were found in
the overall survival of low-grade NHL patients between an initial observation policy and
an interventional approach (Ardeshna et al. 2003).
In aggressive advanced stage FL chemotherapy is extensively used. No standard
chemotherapy regimen exists, but monotherapies such as chlorambucil (with or without
prednisone) or cyclophosphamide, or polychemotherapies such as CVP (combination of
cyclophosphamide, vincristine and prednisone), and CHOP (combination of
cyclophosphamide, doxorubicin, vincristine, and prednisone) have been widely used.
Actively treated patients are followed every 6 to 12 months with clinical examination and
computer tomography for 5 to 10 years (Jyrkkiö et al. 2007).
2.7 RITUXIMAB
Rituximab (Mathera®, Rituxan®) is a chimeric anti-CD20 monoclonal antibody. It
consists of heavy and light chain variable regions of a murine anti-human CD20 mAb
(2B8) and human IgG1/  constant regions. The mouse part contains the antigen
specificity and the human part acts as a trigger of effector systems and diminishes the risk
of anti-antibody rejection. Rituximab is produced in Chinese hamster ovarian cells.
CD20
The target antigen of rituximab is CD20. It is a tetraspan cell surface molecule with an
extracellular loop of 44 amino acids (Tedder, Engel 1994). The molecular weight is 33-37
kDa. The function of CD20 is not known but the non-glycosylated molecule is
phosphorylated and may participate in B-cell growth via intracellular signaling or by
serving as a calcium channel. MS4A1 (Membrane-spanning 4-domain, group A, member
1), the gene coding for CD20, is located on chromosome 11q12-13.
CD20 is specifically expressed in B lymphocytes (Tedder, Engel 1994). Over 90% of B
cell NHLs express CD20, but the expression density is much lower on CLL cells. CD20
is  absent  from  B-lymphoid  stem  cells  but  is  highly  expressed  (about  100000
molecules/cell) by cells from the pre-B-stage throughout B cell maturation. CD20
expression is lost again in mature Ab-secreting plasma cells. The expression profile that
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CD20 has is from the immunotherapy point of view almost ideal: because CD20 is not
expressed by stem cells, a new B cell population can develop after anti-CD20 antibody
treatment, and because CD20 is not expressed by plasma cells the treatment does not
significantly affect immunoglobulin levels. Other benefits for immunotherapy are that
CD20 does not become significantly shed from the cell surface or become internalized
after ligand binding. This is a fundamental feature, because the loss of expression of the
target antigens after first rounds of treatment has been one of the major problems in the
development of new monoclonal antibody therapies for cancer.
CLINICAL EXPERIENCE
Single agent rituximab has been approved for the treatment of relapsed advanced stage
FL. The combination therapy of rituximab with CVP chemotherapy has the indication
for the treatment of advanced stage FL, and the combination therapy with CHOP for the
treatment of DLBCL. In the first clinical trials rituximab monotherapy resulted in
response rates of 40 to 60% for FL-patients with relapsed advanced stage disease and
response rates of 50 to 70% for previously untreated patients with advanced stage disease
(Colombat et al. 2001, McLaughlin et al. 1998). Despite the high initial response rates, the
majority of patients still relapsed after standard rituximab therapy. Therefore, the focus
turned soon towards combining rituximab with various chemotherapy regimens. Phase
III trials showed that a combination of rituximab with CVP or CHOP significantly
improved both the primary response rates (to 81-97%) and the outcome of previously
untreated  FL patients  (Hiddemann et  al.  2005,  Marcus  et  al.  2005).  In  these  trials  PFS
times of rituximab (R) -CVP and R-CHOP-treated patients were significantly longer than
those of patients treated with the respective chemotherapy regimens (median PFS of R-
CVP-treated patients was 32 months versus CVP-treated 15 months, and median PFS of
R-CHOP-treated patients was 50 months versus CHOP-treated 15 months). In relapsed
patients, the response rates and the PFS values were slightly lower than in previously
untreated patients, but still significantly better than in chemotherapy treated patients
(Forstpointner et al. 2004, van Oers et al. 2006)).
Maintenance therapy refers to therapy given after successful primary treatment to
maintain the achieved remission. FL is a good candidate for maintenance therapy because
of the indolent course of the disease, and because the efficacy and favorable side-effect
profile of rituximab make it a very suitable agent for maintenance. In recently published
phase III trials relapsed FL patients were first treated with CHOP or R-CHOP, or with
FCM or R-FCM, and then randomized for maintenance rituximab therapy or observation
(Forstpointner et al. 2006, van Oers et al. 2006). Maintenance therapy gave a significant
survival benefit in both studies for both chemotherapy and immunochemotherapy-
treated patients.
Adverse effects
The treatment with rituximab is usually well tolerated (Kimby 2005). Rituximab induces a
6-month long lymphopenia in most patients, but a full recovery is usually seen in 9 to 12
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months. Adverse hematological effects or opportunist infections are rarely seen.
Infusion-related symptoms like chills, fever, nausea, headache, and general weakness are
common (in about 85% of patients) but usually mild and restricted to the first infusion
only. They are thought to be related to the release of cytokines such as IL-6 and TNF .
More severe infusion-related reactions such as bronchospasm, angioedema, acute lung
injury, and hypotension occur in approximately 10% of patients, but also these reactions
are usually reversible and treatable. However, also very severe consequences of infusion-
related reactions have been reported. They include pulmonary infiltrates, acute
respiratory distress syndrome and cardiovascular events. In some, although very rare,
cases they have been fatal.
2.8 GENE EXPRESSION PROFILING IN FL
Despite of new treatment regimens the clinical course of FL is still very variable and
difficult to predict. The weakness of clinical prognostic indices is that they don’t provide
any information on the biology of tumors. During recent years the gene expression
profiling with microarray technology has provided a method to obtain an overview on
the biology of tumors and revealed factors applicable for risk stratification in FL. Husson
and his colleagues compared FL cells to normal germinal center B-cells. They found
differences in the expression of some transcription factors, cell cycle regulators, and
genes involved in cell-cell interaction (Husson et al. 2002), but did not compare the
results to the disease outcome. Bohen et al. studied rituximab monotherapy treated FL-
patients (Bohen et al. 2003) and compared gene expression profiles of tumors to
responder vs. non-responder distinction. They found that differentially expressed genes
between the groups were often related to cellular immune responses, cytokines,
complement, and T-cell receptor signaling. In a large study by Dave and colleagues
tumor  samples  from  chemotherapy  treated  patients  revealed  two  signatures  of
coordinately regulated genes that together formed a predictor of survival (Dave et al.
2004). Emphasizing the role of microenvironment and immunological feature, many of
the best differentiating genes were expressed by tumor infiltrating T cells, macrophages
or dendritic cells, rather than the lymphoma cells.
In recent years many studies have investigated the contribution of specific cell subsets in
the immunologic regulatory network of tumor microenvironment. A high number of
tumor infiltrating T cells (Alvaro et al. 2006b) especially regulatory T cells (Carreras et al.
2006)  has  been  shown  to  be  associated  with  improved  survival  in  response  to
chemotherapy. In contrast macrophages (Farinha et al. 2005), especially STAT-1
expressing macrophages (Alvaro et al. 2006a), CD57+ cells (Alvaro et al. 2006b), and T
helper cells (Glas et al. 2007) in the tumor tissue have been associated with a poor
prognosis. To date, however, no models are available to predict the outcome in response
to immunochemotherapy.
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3 AIMS OF THE STUDY
General aims of this study were to analyze how rituximab kills lymphoma cells and how
factors related to mechanisms of action of rituximab or biology of tumors correlate with
sensitivity of lymphomas to immunochemotherapy.
Specific aims were:
1) to evaluate the efficiencies of different effector mechanisms of rituximab (I)
2) to study the role of complement regulatory proteins as potential immunotherapy
escape mechanisms of lymphomas (I & III)
3) to study complement activation in blood during and after rituximab infusion (II)
4) to study the effect of intravenously administered rituximab on CNS lymphoma (II)
5) to  study  if  the  expression  of  CD20  and  complement  regulators  in  lymphoma  cells
correlate to treatment outcome of FL patients (III)
6) to study whether differences in gene expression profiles of tumor samples correlate
to treatment outcome of FL patients, and if the differentiating genes reveal potential
tumor surveillance strategies (IV)
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4 MATERIALS AND METHODS
4.1 GENERAL
CELL LINES (I)
Human  lymphoma  cell  lines  were  grown  in  RPMI  1640  medium  (Gibco  Laboratories,
Paisley, UK) supplemented with 10% heat-inactivated fetal calf serum (Gibco), penicillin
(10  U/ml),  streptomycin  (100  g/ml),  and  2  nM  l-glutamine  (Nord  Cell,  Bromma,
Sweden). Cells were grown to the late logarithmic phase before used for cell killing
assays.
The cell lines used were HF-1.3.4 and Raji. HF-1.3.4 originally derives from a patient
with FL and was obtained from Dr. Matti Kaartinen (Department of Bacteriology and
Immunology, Haartman Institute, University of Helsinki, Finland). Raji is a commercially
available Burkitt lymphoma cell line, which we received from Professor Leif Andersson
(Department of Pathology, Haartman Institute, Helsinki, Finland).
ANTIBODIES AND OTHER REAGENTS
Antibodies used in this study are shown in Table 4.
OTHER CHEMICALS (I)
N-formylmethionyl-leucylphenylalanine (N-FMLP) and phorbol myristate acetate (PMA),
both from Sigma Chemicals (St. Louis, MO), were used to stimulate effector cells in cell
killing assays.
COMPLEMENT COMPONENTS AND SERA (I)
Normal human serum was used as a source of C. It was prepared from coagulated blood
of  healthy  volunteers  and  stored  in  aliquots  at  -70°C  until  used.  To  study  CDCC,  C9-
deficient serum (C9DS) was used instead of NHS. C9DS was prepared by absorbing
NHS with Sepharose-coupled-anti-C9 antibody. When C system was desired not to be
active, heat-inactivated human serum (HIS) was used. It was prepared by incubating
NHS for 30 min at 56°C.
4.2 CYTOTOXICITY ASSAYS
COMPLEMENT CYTOTOXICITY ASSAY (I)
To study direct complement-mediated cytolysis 51chromium-labeled lymphoma cells were
incubated for 30 minutes with rituximab and varying concentrations of NHS. The
optimal rituximab concentration for cytolysis assays was found to be 10 g/ml. Portions
of supernatants were removed, and released radioactivity was counted in a
gammacounter.  All  experiments  were  performed  for  at  least  4  times.  Background  was
obtained by measuring the release of 51Cr from samples incubated only with NHS and
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Table 4 Antibodies used in this work.
Antigen Antibody Source Study
Human Human-mouse chimeric Ab





CD19 Anti-CD19 Dakopatts, Glostrup, Denmark II
CD20 Anti-CD20cy Dakopatts, Glostrup, Denmark II
CD20 AP-conjugated anti-CD20 BD Biosciences III
CD20 PerCP-conjugated anti-CD20 BD Biosciences III
CD31 Anti-CD31 Novocastra Laboratories Ltd.,
UK
IV
CD46 GB24 Gift from Prof. John P.
Atkinson (Washington
University School of Medicine,
St. Louis, MO)
I
CD46 10L46 Immunotech S.A, Marseille,
France
I
CD46 FITC-conjugated anti-CD46 BD Biosciences III
CD55 Bric216 Bioproducts Laboratories,
Elstree, UK
I
CD55 APC-conjugated anti-CD55 BD Biosciences III
CD59 Bric229 Bioproducts Laboratories,
Elstree, UK
I
CD59 PE- conjugated anti-CD59 BD Biosciences III
C5b-9
neoantigen




Epha1 Anti-Epha1 Santa Cruz IV
Smad1 Anti-Smad1 Santa Cruz IV
Human Rabbit polyclonal ABs
C1q Anti-C1q (IgG) Dakopatts, Glostrup, Denmark I
C3c Anti-C3 (IgG) Dakopatts, Glostrup, Denmark I
Secondary Antibodies
FITC-conjugated goat anti-rabbit Ig Jackson ImmunoResearch Lab.
Inc., West Grove, PA
I
FITC-conjugated rabbit anti-mouse Ig Jackson ImmunoResearch Lab.




test buffer. To achieve the total lysis reference, the cells were incubated with 0.1 %
Nonidet P-40 detergent.
To evaluate the effect of C regulatory molecules, neutralizing antibodies against CD46
(25 µg/ml of GB24), CD55 (12.5 µg/ml or 25 µg/ml of Bric216), or CD59 (20 µg/ml of
Bric229) were added to the solution along with rituximab. A detailed description of the C
cytolysis assays is in the paper I.
ANTIBODY AND COMPLEMENT-DEPENDENT CELLULAR CYTOTOXICITY ASSAYS (I)
To study rituximab-induced ADCC 51Cr-labeled  lymphoma  cells  were  incubated  for  4
hours with rituximab, PBL and HIS. The contribution of CDCC was studied by replacing
HIS with C9DS. The increase in cytolysis after replacement of HIS with C9DS was taken
to represent CDCC. FMLP or PMA was used for ADCC and CDCC assays to stimulate
PBLs. Analogously to C cytolysis assays portions of supernatants were removed and
counted in a gammacounter. The background values were obtained by measuring the
release of 51Cr from similar samples in the absence of rituximab. To achieve the total lysis
reference, the cells were incubated with 0.1 % Nonidet P-40 detergent.
4.3 IMMUNOLOGICAL TECHNIQUES
IMMUNOFLUORESCENCE MICROSCOPY (I)
To demonstrate and visualize rituximab-mediated C activation, 105 HF-1.3.4  and  Raji
lymphoma  cells  were  incubated  with  various  antibodies  (i.e.  rituximab  and  in  some
experiments with antibodies against C regulators) and NHS, centrifuged onto cytospin
slides, fixed with 4% paraformaldehyde, washed, and treated with BSA to prevent
nonspecific binding of antibodies. The cells were incubated with antibodies against C
components, whose deposition was finally analyzed with an immunofluorescence
microscope. Detailed description of the assay is provided in paper I.
DETECTION OF RITUXIMAB-INDUCED APOPTOSIS (I)
TUNEL (Tdt-mediated dUTP Nick-End Labeling) apoptosis detection system (Promega,
Madison, WI) was used to analyze apoptosis after exposure of lymphoma cells to
rituximab. The fluorescein-12-dUTP-labeled DNA fragments, representing apoptosis,
were visualized by immunofluorescence microscopy after a 24-hour incubation period.
The proportion of apoptotic cells was determined by counting the positively stained and
unstained cells. Detailed description of the method is provided in paper I.
FLOW CYTOMETRY (I & III)
Flow cytometry was used for analysis of C regulator expression on lymphoma cell lines
and for analysis of CD20 and C regulator expression on tumor samples of FL patients.
In paper I HF-1.3.4 and Raji cells were first pretreated with HIS to prevent non-specific
immunoglobulin binding and then with mAbs directed against CD46 (10L46), CD55
(Bric216), or CD59 (Bric229). After treatment with FITC-conjugated secondary
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antibodies, the intensity of immunofluorescence was analyzed and quantified using a
Coulter Profile II (Coulter Electronics, Luton, UK) flow cytometer with a standard filter
set-up. Detailed description of the method is provided in paper I.
The immunofluorescence stainings of patient samples were performed in the context of
routine lymphoma diagnostics. Fresh lymphoma cells were separated from tumor tissue
with fine needle, washed with culture medium (RPMI 1640), and centrifuged to remove
dead cells. One million viable cells were incubated for 30 minutes with conjugated mAbs
directed against  CD20, CD46, CD55, or CD59. Immunofluorescence was analyzed and
quantified using the FACSCalibur Becton Dickinson (Franklin lakes, NJ, USA) flow
cytometer and WinMDI 2.8 program. Detailed description in paper III.
IMMUNOHISTOCHEMISTRY (IV)
Gene expression profiles of lymphoma tissues were analyzed with an mRNA microarray
(as described in section 4.4). The results were verified and the localization of interesting
proteins was evaluated by immunohistochemical stainings. Formalin-fixed, paraffin-
embedded sections from tumor samples were pretreated in an autoclave with 0.01 mol/l
sodium citrate, washed, and stained with anti-EphA1, anti-Smad1 and anti-CD31
antibodies. Vectastain ABC kit reagents (Vector Laboratories, Burlingame, CA, USA)
were used to complete the stainings. The immunoreactions were visualized with 3-amino-
9-ethylcarbazole, and the slides were counterstained with hematoxylin. Detailed
description of the method is provided in paper IV.
EVALUATION OF C COMPONENT LEVELS AND EXPRESSION OF CD19 AND CD20 ON
LYMPHOCYTES (II)
To determine the concentration of C activation product C3a-desArg in plasma and in
CSF the Quidel C3a Enzyme Immunoassay -kit (Quidel Corp., La Jolla, CA) was
employed. Absorbances of samples were analyzed using a Titertek Multiscan
spectrophotometer (Labsystems, Espoo, Finland). The cerebrospinal fluid albumin levels
were determined using LC-Partigen® Albumin plates (Behring Diagnostics, Marburg,
Germany), and serum C3 levels using the Behring Nephelometer Analyzer (Marburg,
Germany). The expression of CD19- and CD20-antigens on blood cells and CSF
lymphocytes were analyzed by immunoperoxidase staining. Detailed methods are
described in paper II.
RITUXIMAB CONCENTRATION IN PLASMA AND CEREBROSPINAL FLUID (II)
To determine the concentrations of rituximab in plasma and CSF, a validated
immunoassay was employed. A 96-well microtiter plate was coated with a polyclonal goat
anti-rituximab antibody. Serial dilutions of patient serum or CSF were added to the wells
and a goat anti-human IgG conjugated with horseradish peroxidase was used for
detection.  Known  amounts  of  rituximab  were  used  to  make  a  standard  curve  on  each
plate. Color was developed by adding substrate to the wells and the absorbances directly




RNA ISOLATION, PURIFICATION AND ANALYSIS OF INTEGRITY (III & IV)
Total RNA was isolated and purified from freshly frozen tumor samples employing a
combination of Trizol (Life Technologies, Rockville, MD, USA) and RNeasy column
purification (Qiagen) technologies. Detailed protocol can be found from the
Supplementary data section of paper IV. RNA integrity was assessed using an Agilent
2100 Bioanalyzer (Agilent Technologies, Massy, France). Reference RNA was derived
from a panel of eleven tumor cell lines.
GENE EXPRESSION PROFILING AND DATA ANALYSES (III & IV)
Isolated RNAs (20 g) were converted to fluorescently (cyanine 3-cDNA or cyanine 5-
cDNA) labeled cDNA using Agilent Fluorescent Direct Label kit. The resulting
reference and test cDNA samples were combined, purified, and hybridized to the Agilent
Human  1A  oligo  microarray  containing  18716  features.  The  microarrays  were  scanned
with a dual laser-based Agilent microarray scanner.
Before hierarchical clustering and supervised analysis the data were pre-processed using
Feature Extraction software (version A.6.0, Agilent Technologies). Detailed descriptions
on data pre-processing and analysis are given in Supplementary Data section of paper IV.
In supervised analysis the samples were first divided into different groups based on
clinical information. Weighted voting algorithm and two-tailed t-test were used to
identify differentially expressed genes, and only the genes showing significant differences
in expression by both methods were further analyzed. For special analysis mRNA
expression levels of CD20, CD46, CD55, and CD59 were calculated from microarray
data of 23 primary R-CHOP treated patients. Detailed description of the method is
provided in papers III and IV.
QUANTITATIVE REAL-TIME PCR (IV)
To verify the microarray results expressions of appropriate mRNAs were measured by
real-time RT-PCR with the TaqMan methodology using a Gene Amp 5700 Sequence
Detection System (Applied Biosystems, Foster City, CA). The detailed description of the
method is available in the Supplementary Data section of paper IV.
STATISTICAL ANALYSES (III & IV)
Chi-square test and Mann-Whitney test were used to compare the baseline characteristics
and expression of mRNA or protein levels. To evaluate the correlation between the data
from microarray, quantitative PCR, and flow cytometry, Spearman correlation coefficient
(rs) was calculated. Survival rates were estimated by the Kaplan-Meyer method and the
differences were compared by the log rank test. Cox univariate test was used to assess the
prognostic value of studied parameters on time to treatment failure (TTF) or PFS.
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TTF  was  determined  as  a  period  between  the  first  day  of  therapy  and  the  date  of  the
documented progression or lack of response, first relapse, or death for any cause. PFS
was determined as an interval between the first day of therapy and the date of relapse.
These analyses were carried out using the SPSS software for Macintosh or Windows
(SPSS, Inc., Chigaco, IL). Detailed descriptions are provided in papers III and IV.
40
5 RESULTS
5.1 EFFECTOR MECHANISMS OF RITUXIMAB (I)
THE APPROACH
Rituximab was demonstrated to kill CD20-positive lymphoma cells by multiple
mechanisms, including activation of the C system, recruitment of cytotoxic cells, and
induction of apoptosis (Reff et al. 1994). Because not all patients respond to rituximab
treatment, even if the lymphomas express CD20 molecules, a more complete
understanding of the effector mechanisms was needed.
THE ABILATY OF RITUXIMAB TO INDUCE CDC, ADCC, CDCC, AND APOPTOSIS IN
VITRO
To analyze the sensitivity of HF-1.3.4 and Raji lymphoma cell lines to rituximab-
mediated  C  killing  the  cells  were  treated  with  rituximab  and  NHS.  The  studies  with
optimized rituximab concentration (10 µg/ml) demonstrated C-mediated killing of 48%
of HF-1.3.4 cells, and 19% of Raji cells.
To  study  the  ability  of  rituximab  to  induce  ADCC,  Raji  and  HF-1.3.4  cells  were
incubated with different concentrations of rituximab, freshly isolated peripheral blood
leukocytes (Effector vs. target ratio 10:1) and HIS. Following a four-hour incubation only
a 10% cytolysis of HF-cells and 6% lysis of Raji cells were observed, and, the absence of
rituximab  did  not  affect  the  killing.  N-FMLP  or  PMA  were  used  to  stimulate  effector
cells,  but only a minor increase (19%) in the lysis  of HF-cells  was observed after PMA
stimulation. No effect was seen in Raji cells or HF-cells after FMLP stimulation.
To examine the role of CDCC, the same test protocols as in the ADCC assays were used
except that HIS was replaced with C9DS. No significant killing was observed when PBLs
were unstimulated or when stimulated with PMA (lysis of HF-1.3.4 cells was about 12%
and that of Raji cells about 15% under both conditions). FMLP stimulation enhanced the
lysis of HF-1.3.4 cells to 24%.
Induction of apoptosis by rituximab was studied using the TUNEL apoptosis detection
system. Following an overnight incubation with rituximab, apoptosis related DNA
fragmentation was observed in 40% of HF-1.3.4 cells, but in only 8% of Raji cells.
Taken together, these results suggest that the cytotoxic effect of rituximab in vitro is
mediated mainly through direct CDC. Neither ADCC nor CDCC were significantly
enhanced by rituximab, but rituximab did induce apoptosis of HF-1.3.4 cells.
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RITUXIMAB-INDUCED C COMPONENT DEPOSITION ON LYMPHOMA CELLS
Deposition of C components on lymphoma cell membranes was studied by treating HF-
1.3.4 cells with rituximab and NHS. The samples were stained with antibodies against
C1q, C3c and C5b-9. Positive C1q cell membrane staining showed that rituximab can
trigger the classical complement pathway, and the deposition of C3 on cell membranes
confirmed an effective rituximab-induced C activation. After staining with anti-C5b-9
antibody (Wu 7.2) MAC complexes were regularly visualized on cell membranes. As an
indicator  that  the  formation  of  MAC  complexes  had  led  to  C-mediated  cell  killing,
normal cell morphology was usually lost.
5.2 NEUTRALIZATION OF C REGULATORS IN VITRO (I)
Surface expression of CD46, CD55, and CD59 on HF-1.3.4 and Raji lymphoma cells was
quantified by flow cytometry analysis after staining with respective antibodies. Both cell
lines expressed strongly CD46, CD55, and CD59 on their surfaces. The HF-1.3.4 cells
displayed greater mean fluorescence intensities for all complement regulators compared
to  Raji  cells.  In  both  cell  lines  CD59 exhibited  the  strongest  expression  and  CD55 the
weakest.
To examine the contribution of the C regulators for protection from C lysis the HF-1.3.4
and Raji cells were exposed to rituximab, NHS, and neutralizing antibodies against
CD46, CD55 or CD59. After treatment with antibodies against CD59 (Bric229), DAF
(Bric216)  or  MCP  (GB24),  loss  of  continuity  of  cell  membranes  and  increased  cell
damage  were  observed.  Neutralization  of  CD46  by  the  GB24  antibody  increased
rituximab-mediated CDC from 48% to 82% in HF-1.3.4 cells and from 19% to 40% in
Raji cells. Neutralization of CD55 with Bric216 resulted in 81% lysis of HF-1.3.4 and of
63% lysis of Raji cells, and neutralization of CD59 with Bric229 in 79% lysis of HF-1.3.4
and  to  81% lysis  in  Raji  cells.  Neutralization  of  all  C  regulators  simultaneously  had  no
further effect to HF-1.3.4 cells (lysis level stayed at around 80%), but increased the lysis
of Raji cells to 93%. C regulators thus considerably affect rituximab-mediated CDC in
vitro. Compared to HF-1.3.4 cells Raji cells were initially less sensitive to rituximab
treatment, but neutralization of CD59 equalized the difference.
5.3 COMPLEMENT ACTIVATION IN BLOOD AND CSF AFTER RITUXIMAB
INFUSION (II)
THE APPROACH
In vitro studies suggested that CDC plays a key role in rituximab-induced killing of
lymphoma cells. No information on the effect of rituximab on central nervous system
lymphoma was available yet many patients suffer form this complication. We studied C
activation  in  blood  and  in  CSF  at  certain  time  points  before,  during,  and  after
intravenously administered rituximab in one patient with anaplastic large cell lymphoma
affecting central nervous system. Blood samples were taken before rituximab treatment
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and 2, 4, 12, 24, and 48 hours after the first and second infusion and CNS samples before
and 4 and 24 hours after the infusions. Both samples were also taken once after third and
fourth infusion.
DISAPPEARANCE OF CD20 POSITIVE CELLS FROM BLOOD DURING RITUXIMAB
INFUSION
Surface marker analysis of blood cells demonstrated that before the first rituximab
infusion 41 % of blood lymphocytes were CD19-positive and 35 % were CD20-positive.
Two hours after beginning of the first rituximab infusion, no lymphocytes were seen
using anti-CD20 antibody. Thereafter the absolute and relative (between 0 and 3 %)
levels of CD20-positive cells remained intact during the whole treatment period. Because
binding of rituximab to CD20 might affect the detection of lymphoma cells with another
CD20 antibody, we also stained them with anti-CD19 antibody. After the first rituximab
infusions the amount of CD19 positive cells stayed below 7% in all measurements. The
results suggest that both normal and malignant B-cells were rapidly and efficiently
eliminated from the circulation of the patient.
C ACTIVATION IN PLASMA AFTER RITUXIMAB INFUSION
To analyze rituximab-induced C activation we measured levels of C3a-desArg, which is
an activation fragment of the central C component C3. The initial C3a-desArg
concentration in plasma before the first rituximab infusion was 55 ng/ml, and it
increased to 138 ng/ml during the first two hours after beginning of the first rituximab
infusion. Thereafter the C3a-desArg concentration decreased in two hours to the basic
level and remained low in all subsequent measurements. No similar C activation was
observed related to the second, third or fourth infusion.
RITUXIMAB CONCENTRATION AND C ACTIVATION IN CSF
Rituximab was also detected in CSF but the concentrations were 500 to 1000 times lower
than in plasma (<0.5 g/ml compared to max. 388 g/ml in plasma). Before rituximab
treatment 10 % of lymphocytes in CSF were CD20-positive, but rituximab had no effect
on  the  amounts  of  CD20  positive  cells  in  the  CSF.  Also,  the  radiological  findings
remained  unchanged.  Neither  an  immediate  increase  in  the  C3a-desArg  level  was  seen.
However, a minor and delayed C activation response was seen 24 to 48 hours (max
13ng/ml) after beginning of rituximab infusion, but it had no effect on the number of
CD20 positive cells in the CSF.
5.4 EFFECT OF CD20 AND C REGULATOR LEVELS ON OUTCOME (III)
THE APPROACH
Our previous results and several other studies demonstrated that neutralization of C
regulatory proteins strengthened the cell killing efficacy of rituximab. In contrast,
expression of C regulators was not shown to correlate to the primary response of
rituximab treatment in vivo (Bannerji et al. 2003, Weng, Levy 2001). To analyze whether
the  expression  of  C  regulators  is  associated  with  outcome  parameters,  we  analyzed
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mRNA levels of CD20, CD46, CD55, and CD59 from pretreatment lymphoma samples
of  23  R-CHOP  treated  FL  patients  and  determined  their  association  with  PFS.  To
validate the gene expression data, we set up a prospective pilot study of 12 patients,
where membrane expression levels of CD20 and C regulators were determined by flow
cytometry from pretreatment lymph node biopsies used for diagnostics.
EVALUATION OF CD20, CD55, CD46, AND CD59 MRNA LEVELS FROM MICROARRAY
DATA
23  R-CHOP  treated  FL  patients  were  included  in  this  study.  21  of  23  (91%)  patients
responded for treatment and 16 (70%) achieved complete response. Median follow-up
was 55 months. Patients were divided into “long-term responders” (PFS>35 months;
n=13) and “short-term responders” (PFS < 23 months; n=10) based on significantly
different outcome rates. High expression levels of CD55 and CD59 in the tumor cells
were more often observed among the short-term than the long-term responders
(p=0.026 and p=0.077), whereas no such association was observed for the CD20 or
CD46 mRNA levels. High CD55 expression levels were also shown to associate with the
high FLIPI score (p=0.02) and low complete response (CR; p=0.04) rates, but not with
the overall response (OR) rates.
In a survival analysis the median PFS time for patients with low CD55 was significantly
longer than for those with high CD55 expression (not reached vs. 20 months, p=0.003).
Also  patients  with  low  CD59  levels  tended  to  have  longer  PFS  than  patients  with
intermediate or high CD59 expression (median PFS not reached vs. 21 months, p=0.09).
EVALUATION OF CD20, CD55, CD46, AND CD59 PROTEIN EXPRESSION BY FLOW
CYTOMETRY
In order to verify the microarray results on C regulation and CD20 expression a
prospective pilot study of 12 immunochemotherapy treated patients was performed. In
this cohort 10 out of 12 patients responded to immunochemotherapy, and two patients
showed a stable disease (SD).  In addition,  two patients received an early relapse after 6
and 13 months. Median follow-up was 23 months. On this basis we divided the patients
into “failured patients” (n=4; two early relapsed patients and two with SD response) and
“patients  in  remission”  (n=8).  Expression  of  CD20,  CD46,  CD55,  and  CD59  in  cells
derived from the lymphoma tissues were evaluated by flow cytometry, but no significant
differences in protein levels between the two groups were observed.
To direct the analysis more specifically to FL cells, the CD20-positive population from
each sample was selected and C regulator levels were compared to CD20 levels in these
cells. The CD20/CD55 ratios tended to be higher among the patients in remission than
in failured patients (mean 2.56 versus 1.01). The difference between the two groups
became more obvious when the CD20 levels were compared to combined average C
regulator levels. Also in Kaplan-Meyer estimates a trend towards a better outcome was
observed in patients with a high lymphoma cell CD20/CD55 ratio (p=0.11) or CD20 vs.
average C regulator level (p=0.018).
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Taken together, differences in the expression of C regulators, especially of CD55, were
observed between FL patients, and in various comparisons these differences were
associated with outcome in response to immunochemotherapy. However, because of the
relatively low number of patients in the study groups the differences did not reach
statistical significance.
For one patient we could also analyze the tumor sample from the relapse. Interestingly,
the expression levels of all three C regulators were higher in this relapse sample as
compared to the pre-treatment sample.
5.5 ASSOCIATION OF FL GENE EXPRESSION WITH TREATMENT
OUTCOME (IV)
THE APPROACH
Because the outcome to immunochemotherapy differs remarkably between individual
patients, and the differences cannot be fully predicted with clinical prognostic indices, we
searched for novel molecular factors correlating with outcome in response to rituximab
and CHOP chemotherapy. Enough mRNA for screening gene expression profiles was
available from 24 samples. Based on clearly different clinical courses the patients were
divided into long-term responders (n=11, PFS; 35 to 66 months), and short-term
responders (n=13, PFS < 23 months). The results were confirmed by
immunohistochemistry using a validation group of 40 FL patients.
IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED BETWEEN LONG AND
SHORT TERM RESPONDERS
Expression patterns of lymphoma tissues from different patients were relatively
homogeneous, and the clusters arising from unsupervised hierarchical clustering did not
associate with clinical parameters. We subsequently conducted a supervised learning
classification and sorted the genes by their degree of correlation with the favorable versus
unfavorable distinction (responder versus non-responder or long-term versus short-term
responder). Weighted voting algorithm and t-test identified numerous genes whose
expression varied between the groups. From all distinctive genes we randomly chose few
biologically interesting genes for qPCR validation (Table 5). smad1 (rs=0.665, p=0.003;
overexpressed in short-term responders), epha1 (rs=0.688, p=0.002; downregulated in
short-term responders), marco (rs=0.529, p=0.020; overexpressed in non-responders), and
mxi1 (rs=0.476, p=0.038) showed correlation between PCR and microarray results, but
differential expression of cul4b mRNA could not be verified by qPCR. The best
correlating genes smad1, epha1 and marco were chosen for further analysis.
qPCR results were compared with the outcome of patients, and considerably longer
median TTF values were associated with low smad1 (p=0.019), low marco (p=0.018), and
high epha1 (p=0.077) qPCR levels. The results suggest that expression of these genes in
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lymphoma  tissue  correlates  with  the  outcome  in  response  to  rituximab  and  CHOP
chemotherapy.




p-value Effect on outcome Function
smad1 0.665 0.003 Unfavorable Signal transduction
epha1 0.688 0.002 Favorable Leukocyte migration
marco 0.529 0.020 Unfavorable Macrophage scavenger
receptor
mxi1 0.476 0.038 Favorable Signal transduction
EPHA1 AND SMAD DETECTION BY IMMUNOHISTOCHEMISTRY
In order to extend the gene expression-based analyses to protein and cellular localization
level, and to confirm the results, we performed immunohistochemical stainings of tumor
samples for EphA1 and Smad1 proteins. The gene expression results concerning marco
could not be verified, because no antibody for paraffin-embedded tissue was available.
Some positive Smad1 staining was observed in malignant lymphocytes, but the most
prominent expression appeared to localize to vascular structures. To get more
information  about  the  vasculature  of  tumor  tissue,  and  to  count  the  vessel  density  in
tumors, CD31 staining was performed, but no difference was found between long and
short-term responders (mean 13.9 vs. 13.2 per TMA core, p=0.74).
The immunohistochemical analysis showed that EphA1 was not observed in malignant
lymphocytes but in the surrounding microenvironment, including vascular endothelia and
granulocytes close to high endothelial venules. The differences at the protein level
between the long-term and the short-term responders were less apparent than the
differences at the mRNA level. The semiquantitative grading of protein expression failed
to correlate reliably with the mRNA data, but in a “hot spot” approach, a good
correlation between mRNA and protein expression of Epha1 (rs=0.628, p=0.003) was
observed. Also EphA1 positive granulocyte counts were higher among long than short-
term  responders  (mean  14  vs.  8  per  TMA  core,  p=0.039).  A  trend  towards  a  better
outcome was seen among the patients having high EphA1 protein expression in their
lymphoma tissue (58 vs. 21 months, p=0.259).
Because Epha1 expression was associated with the outcome at both mRNA and protein
levels, we confirmed the results immunohistochemically in a validation group of 40 R-
CHOP-treated patients. Although no cut-off level for a significant difference between
EphA1 low and high groups could be determined, we observed a trend towards a better
outcome among patients with high EphA1 protein expression (two upper tertiles versus
the lowest tertile) in their lymphoma tissue (p=0.07). Of the 26 patients within the two
upper tertiles, 19 (83%) were in remission (median PFS not reached), and out of 17
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patients within the lowest tertile seven (41%) were in remission (median PFS 43 months).
The results suggest that high EphA1 expression is associated with better PFS of
immunochemotherapy treated FL patients.
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6 DISCUSSION
The addition of rituximab to chemotherapies has significantly improved the treatment
outcome of follicular lymphoma. The main focus of this work was to study how
rituximab actually works, and which factors determine its efficacy. In addition to
scientific interest, the results may provide new approaches for the prediction of the
outcome and for the development of novel strategies to improve the treatment results.
The work was started by a study on the effector mechanisms of rituximab in vitro and
events after rituximab infusion in blood and CSF. During the last couple of years the first
prospective trials of efficacy of immunochemotherapy were completed. Mostly due to
excellent results of this therapy also the focus of the study turned towards factors related
to predicting the outcome in response to immunochemotherapy.
6.1 HOW DOES RITUXIMAB WORK?
Rituximab is known to specifically recognize CD20 positive cells, but how does it exert
its effect on B cell and lymphoma cells? The following chapters will discuss the events
from the distribution of rituximab to CD20 binding and to the effector mechanisms
recruited by rituximab. The initial prerequisite for a cytotoxic effect against a tumor is
that sufficient quantities of rituximab reach the lymphoma tissue.
SERUM LEVELS AND DISTRIBUTION OF RITUXIMAB
Rituximab is usually given at dose of 375 mg/m2. The reported half-life after first
infusion in monotherapy is 76 hours and maximal plasma concentration 205.6 ± 59.9
g/ml (Berinstein et al. 1998). In our case study the maximum rituximab concentration
in blood plasma related to the first infusion was 331 g/ml measured two days after the
beginning of infusion. Achieving a relatively high concentration, this patient also
responded well to the treatment. It has been speculated, whether rituximab levels would
affect the outcome. In one study the levels were indeed higher in responders than in non-
responders (Berinstein et al. 1998). However, the actual level depends on the amount of
accessible CD20, because rituximab is consumed, when bound to circulating or cell
surface CD20 molecules. Therefore we cannot know whether higher rituximab levels
measured  among  responders  were  due  to  a  lower  tumor  burden  and  fewer  CD20
molecules leaving more non-consumed rituximab for measurement, or whether the
metabolism of responders was more favorable leading to higher rituximab concentrations
and better outcome.
Lymphomas often affect the CNS, but only very little information is available on the
access of rituximab to the CSF. We also know that although rituximab has improved the
overall survival of NHL patients it has not influenced the risk of CNS occurrences
(Feugier et al. 2004). The results in this work showed several hundred-fold lower levels of
rituximab in the CSF than in plasma suggesting that the blood-brain barrier can
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effectively prevent the passage of antibodies. In line with previous clinical experience, the
low levels of rituximab in the CSF caused neither a decrease in number of CD20 positive
cells nor any therapeutic effect.
CD20 EXPRESSION
The importance of CD20 expression levels on tumor cells to the outcome of rituximab
treatment has been investigated in various studies, but no clear association has been
observed. In general, low CD20 levels in CLL and high levels in FL cells could explain
their different responses to rituximab treatment but, on the other hand, more variably
responding MCL and DLBCL often express even more CD20 than FLs. In vivo studies
focusing on this question are rare, but a response to rituximab did not correlate to CD20
levels in a study on nine CLL patients (Perz et al. 2002). Instead, numerous in vitro studies
have investigated the influence of variation in CD20 levels on CDC. A relationship
between high CD20 expression by tumor cells and efficiency of CDC has been reported
in some studies (Bellosillo et al. 2001, Golay et al. 2001, van Meerten et al. 2006), but not
in  others  (Golay  et  al.  2000,  Manches  et  al.  2003,  Terui  et  al.  2006).  Van  Meerten  and
colleagues (van Meerten et al. 2006) studied cell lines transfected with different amounts
of CD20 and found that CDC but not ADCC was dependent on CD20 levels. Our data
showed a weak correlation between the outcome and membrane expression of CD20.
The expression of CD20 was slightly higher in patients with a better outcome, but the
differences were small and without a statistically significant survival benefit. If CD20
levels were of major importance, the levels of CD20 would probably be reduced in
relapses. Clinical studies have shown that CD20 negative relapses are very rare in
indolent lymphoma (Davis et al. 2000), but may occur in aggressive lymphoma (Davis,
Czerwinski & Levy 1999, Foran et al. 2001, Kennedy et al. 2002).
6.2 EFFECTOR MECHANISMS OF RITUXIMAB
Effector mechanisms of rituximab have been under intensive research since the first
promising results of this anti-cancer antibody. Better understanding of effector
mechanism would be beneficial for several reasons. Effector mechanisms may e.g. reveal
potential tumor escape mechanism and enable their neutralization, help to develop
rituximab molecule, and give reasons to reconsider the treatment schemes: e.g.
simultaneous administration of chemotherapeutics may be disadvantageous for cellular
effector mechanisms.
The recruitment of cellular (ADCC), and humoral (CDC) effector mechanisms as well as
their combined action (CDCC) and direct cytotoxic effects have all been found to take
place at least under in vitro conditions. Also, the role of possible vaccine-type effects has
been under discussion. Despite numerous studies no consensus has been reached over




RITUXIMAB BINDING TO CD20 INDUCES APOPTOSIS
Antibody binding to CD20 has been reported to induce numerous biological effects.
Most of them are related to the activities of tyrosine kinases and associated with cell cycle
arrest or induction of apoptosis. There has been a wide variation in the amounts of
apoptosis detected under different set-ups and in studies by different investigators
(reviewed by Deans (Deans, Li & Polyak 2002)). Also in this work strong variation in
apoptosis was observed between the studied cell lines (I). In many publications apoptotic
effects have been significantly enhanced by cross-linking of antigen-bound antibodies
with secondary antibodies (hyper-cross-linking) (Ghetie, Bright & Vitetta 2001, Pedersen
et al. 2002, Shan, Ledbetter & Press 1998). The association of variable apoptotic effects
with differences in the translocation of CD20 to lipid rafts has been a fundamental
finding for studies on intracellular signaling (Deans et al. 1998, Polyak, Deans 2002).
Lipid rafts are membrane-microdomains enriched in cholesterol, sphingolipids, and
signal transduction molecules such as Src tyrosine kinases. They are thought to function
as platforms for signaling. Some CD20 antibodies can translocate CD20 to lipid rafts
much more efficiently than others. Besides, the lipid raft formation can be affected by a
different developmental status or the activation stage of the B cell. In lipid rafts, CD20
activates Src-family tyrosine kinases lyn, fyn, lck and p75/85, which initiate apoptotic
cascades (Figure 4). Tyrosine kinase activation leads to phosphorylation of phospholipase
C, Ca2+ influx, caspase-3 activation, and apoptosis (Byrd et al. 2002, Deans et al. 1993,
Deans et al. 1995, Hofmeister, Cooney & Coggeshall 2000, Pedersen et al. 2002, Shan,
Ledbetter & Press 1998, Shan, Ledbetter & Press 2000). In addition to direct
proapoptotic effects, rituximab has been shown to down-regulate survival pathways and
sensitize lymphoma cells to apoptosis-inducing effects of other agents such as
doxorubicin, cisplatin, dexamethasone, fludarabine and retinoids (Alas, Bonavida 2001,
Alas, Emmanouilides & Bonavida 2001, Alas, Ng & Bonavida 2002, Di Gaetano et al.
2001, Ghetie, Bright & Vitetta 2001, Jazirehi et al. 2005, Jazirehi, Bonavida 2005).
CD20-mediated tyrosine kinase activation diminishes the activity of the p38MAPK
signaling pathway. Via downregulation of IL-10 this inhibits constitutive STAT (signal
transducer and activator of transcription) 3 activity and downregulates the anti-apoptotic
protein Bcl-2 (Alas, Bonavida 2001). In non-AIDS-related lymphoma cell lines rituximab
has been shown to downregulate the extracellular signal-regulated kinases 1/2 (ERK1/2)
and NF- B pathways. Down-modulation of these two major survival pathways leads to
the down-regulation of Bcl-xL transcription. Downregulation of both Bcl-xL and Bcl-2
leads to sensitization of lymphoma cells to drug-induced apoptosis.
Even if in vitro studies demonstrated numerous apoptotic pathways, where rituximab may
be involved, only limited information is available on their contribution in clinical settings.
Rituximab has been shown to activate apoptosis-related caspases 3 and 9 (Byrd et al.
2002), and the ratio of caspase-related factors Mcl (myeloid cell leukemia sequence) -1
and Bax has been observed to correlate with the primary response in CLL (Bannerji et al.
2003). Unfortunately, no such information is available for NHL.
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Figure 4. Rituximab-induced apoptotic and chemo-sensitizing pathways.
In lipid rafts rituximab binding can activate lyn and other Src-family tyrosine kinases to initiate
apoptotic cascades via phosphorylation of phospholipase C and chemo-sensitizing cascades via
diminished the activity of the p38MAPK signaling pathway. Rituximab-mediated chemo-
sensitization has been shown to occur also via up-regulation of expression of Raf-kinase
inhibitory protein (RKIP).
COMPLEMENT-DEPENDENT CYTOTOXICITY (CDC)
Rituximab can activate the classical complement pathway by binding the complement
component C1q. The substitution of certain residues (D270, K322, P329, and P331) on
the  CH2 domain of rituximab has been shown to reduce dramatically its C1q binding
capacity (Idusogie et al. 2000). Other structural studies have demonstrated that binding
sites for C1q and Fc-receptors are different, and that one rituximab molecule can, in
principle, induce both CDC and ADCC.
This work has examined rituximab-induced complement activation both under in vivo and
in vitro conditions. Different effector mechanisms of rituximab were compared in vitro,
and  CDC was  demonstrated  to  be  superior  to  the  other  effector  mechanisms.  We also
observed deposition of C components C1q, and C3, and terminal complement
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complexes on the cell surfaces of rituximab and C9-deficient serum-treated lymphoma
cells. This suggests that rituximab activates the classical C pathway, and that C cascade
proceeds to activation of the terminal complement pathway and the MAC formation.
When normal human serum was used as a source of C, the cell morphology was lost due
to direct C mediated lysis. The results are in line with several other in vitro studies, where
effector mechanisms of rituximab were studied against B-cell lymphoma cell lines
(Flieger et al. 2000, Reff et al. 1994, van Meerten et al. 2006) and fresh lymphoma cells
(Bellosillo et al. 2001, Golay et al. 2000, Golay et al. 2001, Manches et al. 2003). The
summary of C-related studies is provided in Table 6.
Some studies  have  shown that  the  efficiency  of  CDC correlates  at  least  partly  with  the
levels of CD20 antigen on target B cells (Bellosillo et al. 2001, Golay et al. 2001, Manches
et al. 2003, van Meerten et al. 2006). In studies with CD20-transfected cell lines Van
Meerten et al. demonstrated a sigmoidal correlation of CD20 expression levels to CDC.
This finding suggests that effective C activation requires a threshold level of CD20 on
target cells.
Activation of the C system has also been associated with the ability of anti-CD20
antibodies to translocate CD20 to lipid rafts (Cragg et al. 2003). Most strikingly B1,
another anti-CD20 antibody (tositumomab), does not translocate CD20 into lipid rafts
nor at all induce C-dependent lysis. Redistribution of CD20-molecules into lipid rafts
leads  to  stronger  C1q  binding  and  activation  of  the  C  cascade  (Golan,  Burger  & Loos
1982). The reason for this is not understood, but one can speculate that a high local
density of CD20 molecules in lipid rafts is required to achieve a needed multi-point
binding of C1q.
Much less information is available on the role of complement-killing in vivo. In an elegant
animal study by Di Gaetano and her colleagues rituximab could efficiently eradicate
murine lymphoma cells (EL4) transfected with human CD20 in immunocompetent mice,
but rituximab was totally ineffective in C1q knock-out animals. (Di Gaetano et al. 2003).
They also showed in vitro that rituximab does not induce significant direct apoptosis and
that depletion of NK, PMN, or T-cells in vivo do not affect to the therapeutic effect of
rituximab.
In this study C activation was evaluated before, during, and after rituximab treatment
with longitudinal blood samples. The C cascade was found to be activated rapidly after
beginning of the first rituximab infusion. The C3 activation product C3a-desArg
concentration increased from 55 ng/ml to 138 ng/ml in two hours, but decreased soon
back to the basic level. Compared e.g. to C activation levels measured in children during
cardiopulmonary bypass the absolute amounts of C3a-desArg remained relatively low
(Meri, Aronen & Leijala 1988), but most probably we missed the “maximum” C3a-
desArg concentration because no samples were taken during the first two hours of the
infusion. After subsequent rituximab infusions no such increase in C3a-desArg
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concentration was observed. This is not surprising, because the surface marker analysis
of blood lymphocytes showed that virtually all CD20 positive cells were already removed
from circulation during the first two hours of the first infusion, and their amounts
remained low in all subsequent measurements. Our patient in this study (II) did not show
notable side effects, but a strong C activating potential of rituximab can also be
considered as a potential cause of adverse effects. In clinical use and especially in patients
with a large tumor burden rituximab can cause an extensive C activation and strong
systemic  effects.  In  a  study  of  five  patients  higher  C3b/c  levels  were  found in  patients
with more severe side effects (van der Kolk et  al.  2001).  Based on this  observation the
authors proposed that the C system may play a key role in inducing the side effects of
rituximab.
The immediate systemic reactions are mainly mediated by the anaphylatoxins C3a and
C5a. They activate mast cells to release histamine, leukotrienes, prostaglandins, cytokines
and other mediators. Anaphylatoxin and cytokine bursts may lead to a systemic
inflammatory response. In minutes up to an hour C5a will also activate
polymorphonuclear leukocytes, which may become aggregated in capillaries. The
obstruction of pulmonary capillaries may lead to an ARDS (adult respiratory distress
syndrome) -like pulmonary dysfunction and hypoxia.
C regulatory proteins
If  CDC  were  an  effective  mechanism  of  the  action  of  rituximab,  neutralization  of  C
regulatory proteins of tumor cells should enhance rituximab-induced killing. In our in
vitro experiments neutralization of CD46, CD55 and CD59 clearly increased C lysis. Flow
cytometry analysis showed that the expression of CD59 was higher than the expression
of CD46 or CD55 in the studied HF-1 and Raji cell lines. In line with this the
neutralization of CD59 proved to be the most effective method to enhance killing.
Membrane bound C regulators have considerably influenced in rituximab-mediated
killing  also  in  other  studies  (Golay  et  al.  2000,  Manches  et  al.  2003,  Terui  et  al.  2006,
Treon et al. 2001, Ziller et al. 2005) (Table 6). Either CD55 or CD59 has been found to
be the most effective regulator, but most of the studies, especially the ones where
neutralizing antibodies were used, concentrated on CD55 and CD59, and CD46 has been
studied much less extensively
In our clinical study (III) we found significantly higher CD55 mRNA levels in the
lymphoma tissues of patients with adverse outcome after R-CHOP therapy as compared
to patients with favorable outcome. No similar differences were seen, when membrane
levels of CD55 proteins were compared. However, when ratios of CD20 and CD55 were
analyzed, the differences were again observed. Of the various C regulators the expression
of CD55 is most actively regulated. A rapid increase in the expression levels of CD55 has
been related with various biological conditions such as sprouting of neurons (Zhang et al.
1998) and activation of neutrophils (Berger, Medof 1987). Also, shedding of CD55 to the
extracellular matrix in vivo and  loss  of  CD55 ex vivo during treatment of tumor samples
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Table 6. A summary of studies in which effector mechanisms of rituximab, expression of C regulators and the effect of neutralization of C
regulators have been investigated. ( =Moderate effect, = Major effect, = no significance, NS= not studied)
Effector mechanism Expression of Neutralization of
Studies with cell lines ADCC CDC CDCC Apoptosis CD20 CD46 CD55 CD59 CD20/C-regA CD46 CD55 CD59
Reff, 1994 Human Lymphoblastoid cell line NS NS
Harjunpää (I) FL and Burkitt lymphoma  (PBL)
Golay, 2000 FL and Burkitt lymphoma
(3 fresh FL samples)
 monocytes /
NK NS
Fliegel, 2000 4 lymphoma cell lines  NS B
Ziller, 2005 2 NHL cell lines C NS
Studies with fresh lymphoma samples
Golay, 2001 33 CLL, 6 PLL, and 6 MCL  NS NS
Bellosillo, 2001 33 CLL, 16 MCL, 4 FL, HCL  NS NS
Manches, 2003 7 FL, 7 MCL, 7 DLBCL, and 7
SLL
 (NK) / 
monocytes/PBLs NS
Terui, 2006 30 NHL D NS  NS
In vivo studies
Weng, 2001 29 NHL patients / (Primary
response) NS  NS
Bannerji, 2003 21 CLL patients / (Primary
response) NS NS 
E NS








CEM cells transfected with
different amounts of CD20 DNA
H
(A) Expression of CD20 versus Average expression of CD46, CD55 and CD59.
(B) In this work CDC has obviously been indicated as CDCC
(C) Novel human CD55 and CD59 Abs were tested
(D) CD55-mediated resistance was overcome with siRNA
(E) CD59 levels were found to be significantly higher in tumor cells, which had survived rituximab therapy.
(F) The mice were injected with human CD20 transfected murine lymphoma cells. ADCC was studied with depletion of NK cells and neutrophils.
(G) Membrane expression / mRNA expression
(H) CD20 levels did affect the efficacy of CDC but not the efficacy of ADCC.
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can also affect the measurements of protein expression. On the other hand the local
amount of CD55 on lipid rafts may be more important in determining the efficiency of
CDC than the total expression of CD55 on cell membranes. Furthermore, besides
membrane bound CD55 also soluble CD55 has some functionally activity (Hindmarsh,
Marks 1998). All these factors may explain why the mRNA expression of CD55 did not
correlate that clearly to membrane expression levels in our studies.
If C regulators provided a clinically relevant escape mechanism against immunotherapy,
one would expect that in possible relapses C resistant clones would be enriched and C
regulator levels in relapsed tumors would be higher than in primary samples. Studies
about this have not been published, but as a single finding we observed an increased
expression of CD46, CD55 and CD59 in a relapsed tumor of one patient compared to
his pretreatment tumor sample. Interestingly, Bannerji and his colleagues analyzed CD55
and CD59 expression levels from pre- and post-treatment samples of seven patients,
whose rituximab treatment did not effectively clear CD20 positive cells from circulation
(Bannerji et al. 2003). The CD55 and CD59 expressions were regularly higher in post-
treatment samples suggesting that subclones expressing higher amounts of CD55 and
CD59 may have been selected during rituximab treatment. It has been demonstrated in
vitro that the treatment of lymphoma cells with sublytic amounts of rituximab can
increase CD55 and CD59 expression levels, and make these cells more resistant to
rituximab-mediated  CDC  (Takei  et  al.  2006).  If  studies  in  future  will  confirm  these
observations, the role of C will be strongly emphasized as a central effector mechanism
of rituximab. The finding also suggests that C regulatory molecules may be determining
factors for the success of immunochemotherapy.
ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
The Fc-part of rituximab is recognized by Fc -receptors of effector cells. Different Fc -
receptors are expressed by monocytes, macrophages, NK-cells, neutrophils, and dendritic
cells, but the precise contribution of various effector cells in ADCC in vivo has not been
fully determined. Some in vitro studies have shown that rituximab induces ADCC in
lymphoma cell lines, but in some others including our in vitro study (I) and animal study
by Di Gaetano (Di Gaetano et al. 2003) effective antibody-dependent responses could
not be induced. The differences in these results may be due to different effector cells.
Especially the studies, which have focused on Fc RIIIA, have emphasized the role of
NK-cells  as  important  effectors.  E.g.  Manches  and  Golay  could  induce  ADCC in vitro
using monocytes and NK-cells as effectors (Golay et al. 2000, Manches et al. 2003), but
neither Manches nor we could demonstrate significant rituximab-induced ADCC, when
human peripheral blood leukocytes were used as effectors. On the other hand, in the
absence of neutrophils, rituximab was less effective in controlling lymphoma cell growth
in SCID mice (Hernandez-Ilizaliturri et al. 2003).
The importance of ADCC was clearly demonstrated in vivo in a xenograft model of
lymphoma using Fc -receptor deficient mice (Clynes et al. 2000). Rituximab-mediated
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tumor cell killing was significantly increased in mice lacking the inhibitory Fc RIIB,
whereas  the  killing  capability  was  totally  lost  in  common -chain  knock-out  animals.  It
has also been observed that genetic polymorphisms of human Fc RIIIa can influence the
therapeutic efficacy of rituximab. Either phenylalanine (F) or valine (V) can be expressed
at position 158 of Fc  receptor IIIa. Fc RIIIa with homozygous VV binds rituximab
with  a  higher  affinity  than  a  receptor  with  phenotypes  VF or  FF (Cartron  et  al.  2002).
Patients with the VV phenotype have also shown better primary responses and longer
PFS times than those carrying the VF or FF phenotype (Cartron et al. 2002). In contrast
to FL Fc R-polymorphism did not show predictive power in CLL (Farag et al. 2004). It
also remains to be shown whether Fc RIIIa polymorphism has impact on
immunochemotherapy treated FL patients. Most studies about rituximab mediated
ADCC have focused on Fc -receptors, but also other receptors may mediate important
activating or inhibiting signals between effector cells and targets (Cartron et al. 2004).
COMPLEMENT DEPENDENT CELLULAR CYTOTOXICITY
Besides MAC formation and lysis of target cells, C activation also leads to opsonization
of  targets  with  C  components  C3b,  inactivated  C3b,  and  C4b.  Complement  activation
products can be recognized by complement receptors expressed on effector cells. In this
manner C activation can recruit cellular effector mechanism to destroy the C opsonized
targets. In addition, the pro-inflammatory anaphylatoxins C5a and C3a stimulate
inflammation and enhance the cytotoxicity of effector cells. CDCC must be taken into
consideration, when studies concerning the effector mechanisms of antibodies are
interpreted. If e.g. C activation is regulated at the C3 stage or one of classical C pathway
components is depleted, along with direct C-mediated lysis also CDCC is blocked.
Similarly,  if  the  effector  cells  are  depleted,  the  actions  of  both  ADCC  and  CDCC  are
inhibited. In many studies where either CDC or ADCC have been studied, the role of
CDCC has been underestimated or even ignored.
COMPARISON OF DIFFERENT EFFECTOR MECHANISMS
Elegant studies emphasizing either the role of C or of cellular mechanism as mediators of
action of rituximab have been published. The interesting question arises: why do some
results  emphasize  the  role  of  ADCC  and  others  that  of  CDC?  It  is  possible  that  both
mechanisms are important and that the lymphoma cells that manage to escape killing by
one mechanism can still be vulnerable to attack by another mechanism. Support to this
theory was obtained from recent studies by van Meerten et al. (van Meerten et al. 2006),
who demonstrated that CDC and ADCC, even if acting independently, can significantly
enhance killing of each other when combined. CD20-transfected CEM T-cells that were
resistant to CDC were still sensitive to ADCC and vice versa.
In addition to combined action also different protocols used in the studies can explain
the observed differences between CDC and ADCC. E.g. ADCC promoting experiments
by Clynes (Clynes et al. 2000) were performed with a s.c. xenograft model in nude mice,
whereas  in  studies  supporting  the  role  of  CDC  by  Cregg  and  Di  Gaetano  tumor  cells
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were administered intravenously (Cragg, Glennie 2004, Di Gaetano et al. 2003). One can
speculate  that  high  levels  of  C  in  plasma  may  favor  CDC  in  the  context  of  i.v.
administered tumors whereas rituximab killing in less vascularized tumors may require
penetration of effector cells. On the other hand, Gong et al. demonstrated by using
human CD20-transfected mice that the treatment with anti-CD20 antibody leads to a
rapid clearance of circulating B-cells through the reticuloendothelial system (Gong et al.
2005). The elimination of circulating cells was strongly dependent on Fc-receptor related
mechanisms, and the access of lymph node B cells to circulation was shown to be crucial
for their depletion. In contrast, the elimination of B cells from the mantle zones, from
where they are ineffectively mobilized, was demonstrated to be dependent on C activity.
In the introduction a cancer immunoediting theory concerning de novo oncogenesis was
presented (Dunn, Koebel & Schreiber 2006, Dunn, Old & Schreiber 2004a, Dunn, Old
& Schreiber 2004b). According to the theory the immune system can recognize and
destroy the majority of transformed cells generated in the human body. However, few
tumor cells are sometimes resistant to immune attack; they can survive and undergo slow
transformation during subsequent years at the immunoediting phase. They often remain
hidden without causing a clinical disease until new transformation or other events
favoring the tumor cells lead to an escape from immune control. I hypothesize that
analogous events may occur during therapeutic interventions. Immunochemotherapies
have shown excellent primary response rates and the majority of patients have achieved
at least a partial response. The overall response rates of immunochemotherapy in FL
have  been  around  80  to  95%  and  complete  response  rates  between  40  and  70%.  The
achievement of complete response has been shown to predict a longer progression free
survival, but at least until recently, most patients with an initial complete response still
tend to relapse during subsequent years. This obviously means that some tumor cells can
resist the initial therapy, but that an intact immune system, and nowadays sometimes also
maintenance therapy with rituximab, keeps them under control until new changes in gene
expression lead to new escape mechanisms and cause clinical relapse. As could be
expected, relapsed tumors are usually more resistant to rituximab and chemotherapeutics
than the primary tumors, and even responding tumors tend to re-relapse earlier (Davis et
al. 2000, Forstpointner et al. 2004, van Oers et al. 2006).
In animal studies cellular mechanisms have been shown to be important in the
prevention of tumor development. In addition, the tumors developing in
immunodeficient mice have been demonstrated to be more immunogenic than the
tumors growing in wild type animals. This suggests that tumors must develop relatively
efficient defence mechanisms against cellular immunity. In contrast significant
differences in C regulator expression between different tumor types and individual
tumors exist, but these differences do not seem to correlate with the behavior of the
tumors. Our unpublished data failed to demonstrate difference in the incidence of
chemically induced tumors between C deficient mice and WT mice. This suggests that
the  C  system  has  only  a  minor  role  in  the  prevention  of  primary  tumor  development.
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Fishelson has proposed that it may be in fact the absence of a selective force that keeps
the C regulator levels variable (Fishelson et al. 2003). Complement regulators are
constitutively expressed, and in the absence of effective C activating conditions the basal
expression is sufficient to keep the tumors alive. As a result the growing tumors develop
relatively effective defense mechanisms against cellular immunity, but not necessarily
against C.
Another potential explanation for a less extensive C regulator expression on lymphoma
cells arises from the special features of B cell development. During their maturation
process, B cells are subjected to a series of positive and negative selection steps that
control the na ve cell repertoire that has left the bone marrow. The selection is based on
the exposure of B cells to self- and non-self structures at different stages of development.
Negative selection leads to induction of apoptosis and deletion of autoreactive clones.
The C system has been demonstrated to modify the selection processes and to participate
in the clearance of apoptotic cells. To support C-mediated selection and to prevent the
survival of autoreactive B cells, it can be speculated that it is beneficial that B cells do not
express such a high amount of C regulators on their cell surfaces. This may explain why
also malignant B cells express C regulators less extensively that many other tumor types.
The infusion of rituximab may be one of the first times when lymphomas are exposed to
an effective C attack. Therefore it is not surprising that rituximab is effective in killing
them. Rituximab-triggered C attack also provides the expected “selective force”, which
can enrich C resistant clones. As mentioned above tumor cells must have effective
mechanisms to cope with cellular immunity to stay alive in body, so they may be indeed
the differences in the C resistance that separate rituximab-responders from non-
responders.
6.3 GENE EXPRESSION PROFILING AND THE ROLE OF TUMOR
MICROENVIRONMENT IN THE PATHOGENESIS OF FL
Clinical results have demonstrated that despite the excellent primary responses, the
clinical course of immunochemotherapy-treated patients varies significantly and the
prediction of outcome of individual patients is difficult. Cytogenetic studies have
confirmed that follicular lymphoma is a group of clonally heterogeneic diseases. Genetic
differences are thought to affect the clinical diversity together with microenvironmental
factors and additional genetic alterations that occur during the course of the disease.
Study IV searched for biomarkers related to the variable clinical course by evaluating
gene expression profiles of lymphoma tissues of patients treated with R-CHOP. The idea
was that this approach would provide a general overview of variability of biological
features between lymphoma samples and would possibly reveal individual genes whose
expression correlated to the outcome. In general, the expression patterns were relatively
homogeneous, but certain genes with predictive power were identified. The genes
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implicated in the long-term versus short-term outcome distinction included multiple
regulators for cell growth, apoptosis, and immune responses. Interestingly, the genes
whose expression was further validated with immunohistochemistry (EphA1, Smad1)
were  shown  to  be  mainly  expressed,  not  in  the  lymphoma  cells  themselves,  but  in  the
cells of the tumor microenvironment.
During  the  recent  years  several  studies  with  analogous  results  have  been  published  in
follicular lymphoma. Dave et al. introduced an outcome predictor based on immune
response-related gene expression signatures (Dave et al. 2004). A favorable prognosis
profile included a number of genes strongly expressed by T cells and an unfavorable
prognosis profile included genes related to dendritic cells and macrophages. In line with
these results high macrophage counts were found to be associated with an aggressive
disease (Alvaro et al. 2006b, Farinha et al. 2005), and high number of tumor infiltrating
T-cells (Alvaro et al. 2006b), and especially of T-regulator cells (Carreras et al. 2006) with
favorable prognosis. In our microarray data mRNA of the scavenger receptor on
macrophages marco was overexpressed in the poor-prognosis patients. The expression of
Marco in the tumor tissue may reflect a lymph node response to the tumor cells, because
it has also been shown to be involved in tumor antigen stimulated phagocytosis by
dendritic cells (Grolleau et al. 2003).
Glas et al. (Glas et al. 2005) could not verify the results by Dave, nor did they find any
association between the macrophage count and outcome. Instead, they built their own
81-gene predictor, which could differentiate responders from non-responders, but could
not predict the long-term outcome (Glas et al. 2005). The authors speculated that the
outcome cannot be predicted using diagnostic samples because additional genetic
mutations during the course of disease markedly affect the risk for transformation. This
raises the question about the role of transformation for outcome. A consensus has been
reached in that histologic transformation of FL to DLBCL is related to a worse
prognosis, but early relapses are only sometimes related to transformation, and
transformation can explain only a part of the diversity of the disease.
To explain the variable clinical behavior of FL with vulnerability of FL cells to
transformation De Jong proposed a dual pathway model for the pathogenesis of FL (de
Jong 2005). After the initial t(14;18) translocation different secondary alterations result in
the development of prognostically different diseases. In the poor prognosis pathway,
genomic alterations (Höglund et al. 2004) drive the process towards an activated
immunologic state and a genomic instability. Follicular dendritic cells and tumor
infiltrated T cells are thus highly activated, but they are dysfunctional with respect to
homing of B cells. This results in an increased amount of interfollicular tumor cells, and
an early vulnerability to the transformation of FL into DLBCL. In addition, the
activation of T-helper 1 (Th1) cells may reflect immunologically active state and predict
an early transformation (Glas et al. 2007). Alternatively, according to the theory of de
Jong, in the good-prognosis pathway, genomic alterations accumulate at a slow pace
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resulting in the stabilization of tumor cells. A mutagenic pressure from the
microenvironment  is  lower,  when  follicular  dendritic  cells  and  T-cells,  even  if  they  are
present at high density, are in an inactive state. Under these conditions the lymphoma
cells are relatively resistant to transformation and the prognosis is better.
Besides the importance of C regulators and marco, our data revealed that the expression
of Smad1 and EphA1 in non-malignant cells of tumor microenvironment was associated
with a different outcome. Smad1 is a transcription factor related to BMP and TGF-
signaling and EphA1 is a receptor tyrosine kinase, which has been found to be involved
in trans-endothelial migration of T-cells (Aasheim, Delabie & Finne 2005, Sharfe et al.
2002, Sharfe et al. 2003). EphA1 was detected in the vasculature and in granulocytes
located close to high endothelial venules. The finding offered us a possibility to speculate
that EphA1, which was overexpressed in the long-term-responders, may improve the
ability of granulocytes to invade the malignant lymph nodes and to enhance rituximab-
mediated ADCC.
The published molecular prognostic markers related to follicular lymphoma are
summarized in Table 7.In the above mentioned microarray studies the treatment
regimens were relatively variable and often not specified in detail by the authors, whereas
our study focused on immunochemotherapy-treated patients. If we compare our results
to the results of others, we can find both similarities and differences. Along with others
we found outcome-associated genes related to the regulation of cell growth and immune
responses, but also genes possibly related to the efficacy of rituximab-mediated CDC and
ADCC (especially CD55 and epha1).  It  is  not  surprising  that  these  genes  were  not
demonstrated in other studies where the treatment was not based on rituximab.
6.4 STRATEGIES TO IMPROVE EFFICIENCY OF MABS IN
IMMUNOTHERAPY
Studies on the effector mechanisms of rituximab and on outcome-related biological
factors have revealed tumor-related resistance mechanisms which lymphoma cells can
use to escape immunotherapy. These findings establish a basis for strategies to improve
the efficacy of the therapies. The strategies can be divided into (1) new methods to
administer drugs, (2) improved selection criteria for patients, who are likely to benefit
from immunochemotherapy, (3) methods to improve the response of target cells to
rituximab, and (4) modifications to treatment regimens.
NOVEL METHODS TO ADMINISTER RITUXIMAB
The results in this work have shown that intravenously administered rituximab does not
enter the central nervous system. Low levels of rituximab in CSF cannot reduce the
amount  of  CD20 positive  cells  in  the  CSF nor  induce  any  therapeutic  effect.  We have
suggested that intrathecal administration of rituximab might be a tempting alternative for
patients with lymphoma involving the CNS (II). Recently this approach was tested by
others. Intrathecal rituximab has been shown to be effective against leptomeningeal
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lymphoma, but ineffective against parenchymal disease (Schulz et al. 2004). However,
Takami and his colleagues injected intraventricularly rituximab and autologous serum as a
source  of  C  to  one  patient  (Takami  et  al.  2006).  They  demonstrated  a  late  clinical
response against parenchymal CNS lymphoma, but because of infection problems only
one infusion was given, and the disease soon progressed.
Table 7. The published molecular prognostic markers related to follicular lymphoma. Also
predictive factor related to immune system reactions are included in table.
Factor Mechanism Effect Reference
BCL-2 expression Anti-apoptotic Unfavorable








Bcl-XL Anti-apoptotic Unfavorable Zhao et al. 2004)
Cyclin B1 Cell cycle regulation Favorable Björck et al. 2005
Epha1 Migration Favorable Paper IV
Smad1 Signal transduction Unfavorable Paper IV
Marco Macrophage receptor Unfavorable Paper IV
CD55 Regulator of C activation Unfavorable Paper III
Fc -receptor






DLBCL Unfavorable de Jong 2005
Activation of T-helper 1 Unfavorable Glas et al. 2007






(IR-1) versus IR-2 Variable Dave et al. 2004
81-gene predictor Variable Glas et al. 2005
IMPROVED PATIENT SELECTION
To identify beforehand the patients to whom immunochemotherapy most probably is
not effective, more accurate methods to select patients are needed. As discussed above
clinical prognostic indices does not provide any information about tumors. Desired
valuable molecular information on lymphomas can be received by gene expression
profiling but it cannot be incorporated into routine diagnostics or clinical evaluation of
patients. A better approach would be to use less laborious and costly methods, such as
flow cytometry, immunohistochemistry, or qPCR. The latter two approaches have been
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utilized in recent studies on diffuse large B-cell lymphoma (Berglund et al. 2005, Hans et
al. 2004). In this work we have used flow cytometry, qPCR and immunohistochemistry
for validation of microarray data, and demonstrated that mRNA analyses can be
extended to protein studies. We have also presented some candidate proteins, which
might discriminate long surviving patients from those whose disease relapses early. If
future studies with larger patient cohorts confirmed our results, pre-treatment analysis of
these  parameters  might  provide  a  practical  tool  for  the  selection  of  patients  or  for  the
prediction of outcome. By now none of the recently discovered molecular predictors has
been incorporated into widespread clinical use, but most probably in near future
prognostic indices based on the molecular markers, or indices combining clinical and
molecular factors will be proposed.
MECHANISMS OF RESISTANCE TO RITUXIMAB
A great number of NHL patients treated with rituximab monotherapy become resistant
to rituximab. In a re-treatment study of patients with relapsed follicular or low-grade
NHL, only 40% of patients who had a prior partial or complete response to single-agent
rituximab responded to re-treatment at the time of relapse (Davis et al. 2000). The
mechanism of resistance is not clearly defined, but most probably the development of
resistance is a result of multiple events. The discovery of factors influencing in the
efficacy  of  rituximab treatment  has  also  revealed  tumor  escape  mechanisms  utilized  by
lymphomas. These factors can be categorized as (1) factors influencing the number of
circulating CD20-positive cells or the level of CD20 expression, (2) C resistance
mechanisms, (3) ways to affect ADCC, and (4) ways to modify CD20-mediated signaling.
The amount of CD20 molecules
Approaches to increase CD20 expression on B-cells are limited, but in one study CD20
expression  was  shown  to  be  increased  after  treatment  with  TNF ,  GM-CSF  and  IL-4
(Venugopal et al. 2000), and in another study after treatment with bryostatin-1 (through
the ERK signal transduction pathway) (Wojciechowski et al. 2005). Clinical studies with
these agents have not been published, so their clinical impact remains to be shown.
Kennedy et al. have demonstrated that rituximab-opsonized CLL cells were temporarily
removed from the circulation by the mononuclear phagocytic system, and released back
after the rituximab-CD20 complexes were removed by phagocytic cells (Kennedy et al.
2004). They proposed that this escape mechanism would produce CLL cells that lack
CD20 molecules and simultaneously could explain the loss of rituximab sensitivity
observed in some CLLs. To overcome this escape mechanism the authors suggested that
it might be worth of engineering a modification of anti-CD20 antibody, which would
activate C but not bind to Fc-receptors. However, this kind of modification would also
loose the ADCC inducing capability of rituximab.
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Enhancement of C activity
Complement-activating potential of mAbs with different mouse isotypes varies
considerably. Isotype switching, humanization and other types of manipulation may be
used  to  strengthen  the  C  activating  power  of  antibodies.  Since  rituximab  already  is  a
chimeric mAb of the C activating human IgG1 isotype, these procedures are no longer
practical.
Neutralization of C regulatory molecules could be a useful method to enhance rituximab-
mediated CDC also in vivo. Because also all normal cells need C regulatory molecules on
their  cell  surfaces,  the neutralization should be directed specifically  to lymphomas.  This
could be achieved by generating bispecific or cross-linked antibodies, which would
recognize a tumor-specific antigen and a C regulator molecule (Blok et al. 1998). The
potentially harmful effects of antibody binding to normal tissues could be prevented by
composing constructs with a high-affinity tumor-detection arm (or antibody) and a low-
affinity  C  regulator-detection  arm  (Gelderman  et  al.  2002,  Harris  et  al.  1997).  Another
approach would be to modulate C regulator expression with cytokines, but as mentioned
earlier many cytokines have usually been demonstrated to have rather an up-regulative
than a down-regulative effect. Interestingly, however, fludarabine treatment has been
shown to down-regulate CD55-expression levels in B lymphoma cells. It has also made
lymphoma cells more vulnerable to lysis by rituximab (Di Gaetano et al. 2001). The
recently described siRNA technology (Elbashir et al. 2001) provides yet another method
to block the expression of C regulators. Terui and colleagues knocked-down CD55
expression from freshly isolated lymphoma cell lines with siRNA (Terui et al. 2006) and
received cells,  which  were  more  vulnerable  to  rituximab  treatment.  Nagajothi
demonstrated genetic and biochemical methods to decrease the expression of GPI-
anchored  proteins  (Nagajothi  et  al.  2004),  but  studies  in  the  context  of  rituximab have
not been published.
Kennedy and his colleagues have suggested that deficiencies in one or more C
components  may  be  associated  with  a  failure  of  some  patients  to  achieve  effective
response to rituximab (Kennedy et al. 2004). They observed that the C component C2
was sometimes consumed out during rituximab treatment of CLL with high cell
densities,  and  suggested  that  this  might  explain  the  poor  response  of  some patients  to
rituximab. As a solution they proposed to use additional C2 or a more universal C
source, like plasma infusion together with rituximab (Kennedy et al. 2004).
CD20 expression levels have been demonstrated to have a sigmoidal correlation with
CDC (van Meerten et al. 2006). This suggests that the induction of effective C activation
requires  a  certain  minimum  level  of  CD20  on  cell  surfaces.  High  density  of  CD20
molecules leads to stronger binding of antibody and C1q molecules and enables classical
pathway activation to proceed efficiently to terminal pathway activation. In an attempt to
improve complement activation after rituximab treatment, an antibody directed to iC3b
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was added to rituximab and complement-treated tumor cells (Kennedy et al. 2003). As a
result more C3b molecules accumulated onto the tumor cell surfaces and the cells were
killed more efficiently by complement.
Enhancement of ADCC activity
The precise contribution of various effector cells to rituximab-mediated ADCC remains
unclear but at least NK-cells and monocytes, and in some studies also PMNs, have been
demonstrated to contribute to ADCC activity. Several cytokines have potential to
increase the number of different types of leukocytes and they have been proposed to
enhance ADCC activity. In animal studies IL-2 has been shown to promote NK-cell
development and activation (Hooijberg et al. 1995). Thereby it may enhance also
rituximab activity. When IL-2 was given together with rituximab, a positive correlation
between  high  NK cell  count  and  a  favorable  clinical  response  was  found (Gluck  et  al.
2004). Clinical trials have also shown increased progression free survivals for patients
treated with rituximab and IFN-  (Kimby 2002). Also granulocyte macrophage colony-
stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) may
enhance the cytotoxic activity of effector cells in ADCC (Kimby 2002, Voso et al. 2002).
We used leukocyte stimulators PMA or FMLP to stimulate peripheral blood leukocytes in
vitro, but no effect on rituximab-triggered ADCC was observed. However, the promising
clinical results of combining IFN-  to rituximab therapy and the desire to avoid the use
of chemotherapeutics have aroused interest to study further the efficacy of cytokine-
adjusted  rituximab therapies.  Also  adoptive  transfer  of  LAK cells  was  demonstrated  to
improve the rituximab-mediated ADCC, but this study only had seven patients (Berdeja
et al. 2007).
The interaction of antibody with Fc -receptors of effector cells is a fundamental step in
the triggering of ADCC. In several studies the balance between activating (CD16, CD32
(Fc -RIIa)  and  CD64)  and  inhibiting  (CD32  -  Fc -RIIb)  Fc-receptors  has  been
investigated and a correlation to the efficacy of ADCC has been observed (Weng, Levy
2003). Therefore approaches to influence this balance or molecular engineering of the Fc
region of rituximab to increase its affinity to Fc-receptors may be effective in enhancing
ADCC (Shields et al. 2001).
Altered signaling
Non-toxic sensitizing agents (e.g. drugs, chemotherapeutics, rituximab) alter gene
expression profiles by regulating the expression levels of anti- and pro-apoptotic proteins
(Jazirehi et al. 2001, Jazirehi, Bonavida 2005, Maldonado, Melendez-Zajgla & Ortega
1997). The use of such agents could remove inhibition blocks of apoptosis or lower the
threshold to apoptosis and may be used prior to the proper cytotoxic therapy. According
to a model proposed by Jazirehi (Jazirehi, Bonavida 2005) cytotoxic secondary agents can
thereafter destroy the targets at lower concentrations and with fewer side effects.
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ALTERNATIVE METHODS TO TREAT IMMUNOCHEMOTHERAPY RESISTANT PATIENTS
By now, if immunochemotherapy has proven not to be effective, the only alternative has
often been to change treatment regimen. Currently available approaches for these
situations include use of rituximab with other chemotherapeutics, autologous stem cell
transplantation, maintenance therapy, and radioimmunotherapy.
Stem cell transplantation and maintenance therapy
When active treatment of relapses is indicated, intensive treatment i.e. consolidation
high-dose chemotherapy with autologous (HDT/ASCT) or allogeneic stem cell
transplant is worth considering. Randomized studies have shown that HDT/ASCT
prolongs the progression-free survival (Freedman et al. 1999, Lenz et al. 2004, Schouten
et al. 2003) of chemotherapy-treated patients, but that initial treatment with
immunochemotherapy gives a similar effect. Intensive treatment is considered in Finland
for early relapsed patients with high FLIPI scores ( 3) and for patients with transformed
disease (Jyrkkiö et al. 2007). Also allogeneic hematopoietic stem cell transplantation is a
potentially curative treatment, but treatment-related mortality is higher compared to
autologous transplantation (van Besien et al. 2003). Allogeneic transplantation may be
considered for young patients relapsed after ASCT.
Not all patients are suitable for intensive treatment, but FL is also a good candidate for
maintenance therapy. Maintenance treatment with rituximab has given survival benefit
for patients primarily treated with either chemotherapy or immunochemotherapy
(Forstpointner et al. 2006, van Oers et al. 2006) but not for rituximab-resistant patients.
Radioimmunotherapy in follicular lymphoma
In addition to rituximab, radiolabeled non-humanized anti-CD20 antibodies 90Yttrium-
ibritumomab and 131Iodine-tositumomab have been approved for treatment of FL. The
major problem with these agents is a two to four weeks lasting myelosuppression. It is
usually observed one to two months after radioimmunotherapy, but can be controlled
with dose escalation. In a phase III study of relapsed follicular and other indolent NHLs
90Yttrium-ibritumomab  was  compared  to  rituximab  (Witzig  et  al.  2002).  The  overall
response rate was higher for Y-ibritumomab (80% versus 56%), but there was no
significant difference in times to progression. 131Iodine-tositumomab has been compared
to chemotherapy in clinical trials with superior response rates (Kaminski et al. 2001,
Press et al. 2003). No trials comparing radioimmunotherapy to immunochemotherapy
have been conducted. In Finland, the use of radioimmunotherapy has by now been
limited to special cases.
6.5 FUTURE PROSPECTS
Specific immunotherapies have started a new era in cancer treatment. The research field
of immunotherapy is young and we are still drawing the rough lines and characterizing
the basic features. The research is still giving more clues than answers. In this thesis the
effector mechanism of rituximab, and factors related to its efficacy in the treatment of
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FL patients have been investigated. We have demonstrated novel molecular markers
(EphA1, Smad1, Marco, CD55) whose expression correlate to clinical course of
immunochemotherapy treated patients, and emphasized the role C as an important
effector mechanism of rituximab. This indicates that more attention needs to be paid to
the properties of monoclonal antibodies. Modification and engineering of antibody
molecules provide practical tools for effective and specific cancer therapy.
After rituximab several other monoclonal antibodies have already been launched for
cancer therapy and many more are coming. Making the study of rituximab even more
interesting the experience we receive from rituximab can be utilized also in the
development of novel antibodies in the future. It is probable that the mechanisms of
action of rituximab and at least some of the obstacles we are facing with rituximab
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